LivaNova (LIVN) 10-Q 2 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Jul. 26, 2018
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Entity Registrant Name	LIVANOVA PLC
Entity Central Index Key	1,639,691
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		48,591,937
Trading Symbol	LIVN

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Net sales	$ 287,498	$ 255,843	$ 537,896	$ 482,668
Cost of sales	91,993	84,023	176,591	163,991
Product remediation	1,542	1,723	5,257	931
Gross profit	193,963	170,097	356,048	317,746
Operating expenses:
Selling, general and administrative	123,439	94,264	227,600	181,604
Research and development	34,215	33,833	65,967	54,219
Merger and integration expenses	4,409	3,512	7,369	5,698
Restructuring expenses	476	2,597	2,357	12,627
Amortization of intangibles	9,817	8,116	18,618	16,076
Total operating expenses	172,356	142,322	321,911	270,224
Operating income from continuing operations	21,607	27,775	34,137	47,522
Interest income	232	252	679	525
Interest expense	(3,006)	(1,578)	(5,117)	(3,893)
Gain on acquisitions	0	39,428	11,484	39,428
Foreign exchange and other (losses) gains	(70)	(2,837)	(343)	336
Income from continuing operations before tax	18,763	63,040	40,840	83,918
Income tax (benefit) expense	(1,030)	3,259	2,863	8,914
Losses from equity method investments	(265)	(14,102)	(627)	(16,098)
Net income from continuing operations	19,528	45,679	37,350	58,906
Net (loss) income from discontinued operations	(4,462)	1,819	(9,011)	(137)
Net income	$ 15,066	$ 47,498	$ 28,339	$ 58,769
Basic income (loss) per share - continuing operation (in Dollars per Share)	$ 0.40	$ 0.95	$ 0.77	$ 1.22
Basic income (loss) per share - discontinued operation (in Dollars per Share)	(0.09)	0.04	(0.18)	0
Basic income (loss) per share (in Dollars per Share)	0.31	0.99	0.59	1.22
Diluted income (loss) per share - continuing operation (in Dollars per Share)	0.40	0.95	0.76	1.22
Diluted income (loss) per share - discontinued operation (in Dollars per Share)	(0.09)	0.03	(0.18)	0
Diluted income (loss) per share (in Dollars per Share)	$ 0.31	$ 0.98	$ 0.58	$ 1.22
Shares used in computing basic income (loss) per share (in Shares)	48,487	48,140	48,406	48,104
Shares used in computing diluted income (loss) per share (in Shares)	49,338	48,303	49,263	48,241

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 15,066	$ 47,498	$ 28,339	$ 58,769
Other comprehensive (loss) income:
Net change in unrealized gains (losses) on derivatives	801	(1,310)	(456)	(3,943)
Tax effect	(192)	559	111	1,283
Net of tax	609	(751)	(345)	(2,660)
Foreign currency translation adjustment, net of tax	(58,154)	56,587	(47,601)	72,017
Total other comprehensive (loss) income	(57,545)	55,836	(47,946)	69,357
Total comprehensive (loss) income	$ (42,479)	$ 103,334	$ (19,607)	$ 128,126

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 47,380	$ 93,615
Accounts receivable, net of allowance of $9,561 at June 30, 2018 and $9,418 at December 31, 2017	261,915	282,145
Inventories	157,831	144,470
Prepaid and refundable taxes	51,944	46,274
Assets held for sale	0	13,628
Assets of discontinued operations	0	250,689
Prepaid expenses and other current assets	35,621	39,037
Total Current Assets	554,691	869,858
Property, plant and equipment, net	186,156	192,359
Goodwill	965,697	784,242
Intangible assets, net	798,434	535,397
Investments	21,130	34,492
Deferred tax assets, net	65,539	11,559
Other assets	5,489	75,984
Total Assets	2,597,136	2,503,891
Current Liabilities:
Current debt obligations	110,588	84,034
Accounts payable	86,914	85,915
Accrued liabilities and other	86,153	78,942
Taxes payable	23,089	12,826
Accrued employee compensation and related benefits	61,276	66,224
Liabilities of discontinued operations	0	78,075
Total Current Liabilities	368,020	406,016
Long-term debt obligations	50,413	61,958
Contingent consideration	178,449	33,973
Deferred income taxes liability	154,404	123,342
Long-term employee compensation and related benefits	29,328	28,177
Other long-term liabilities	33,488	35,111
Total Liabilities	814,102	688,577
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Ordinary Shares, £1.00 par value: unlimited shares authorized; 48,661,493 shares issued and 48,584,123 shares outstanding at June 30, 2018; 48,290,276 shares issued and 48,287,346 shares outstanding at December 31, 2017	75,269	74,750
Additional paid-in capital	1,744,262	1,735,048
Accumulated other comprehensive (loss) income	(2,633)	45,313
Accumulated deficit	(33,755)	(39,664)
Treasury stock at cost, 77,370 shares at June 30, 2018 and 2,930 shares at December 31, 2017	(109)	(133)
Total Stockholders’ Equity	1,783,034	1,815,314
Total Liabilities and Stockholders’ Equity	$ 2,597,136	$ 2,503,891

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Parenthetical) $ in Thousands	Jun. 30, 2018USD ($)shares	Jun. 30, 2018£ / shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2017£ / shares
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance | $	$ 9,561		$ 9,418
Ordinary shares, par value (in Pounds per Share) | £ / shares		£ 1		£ 1
Ordinary shares issued (shares)	48,661,493		48,290,276
Ordinary shares outstanding (shares)	48,584,123		48,287,346
Treasury stock (shares)	77,370		2,930

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating Activities:
Net income	$ 28,339	$ 58,769
Non-cash items included in net income:
Depreciation	16,624	17,998
Amortization	18,609	23,095
Stock-based compensation	14,220	8,564
Deferred income tax benefit	(9,909)	(19,791)
Losses from equity method investments	1,838	18,482
Gain on acquisitions	(11,484)	(39,428)
Impairment of property, plant and equipment	480	4,581
Amortization of income taxes payable on inter-company transfers of property	5,166	17,770
Remeasurement of contingent consideration to fair value	(5,546)	155
Other	(943)	1,675
Changes in operating assets and liabilities:
Accounts receivable, net	21,799	(15,912)
Inventories	(11,285)	(6,927)
Other current and non-current assets	(15,786)	(13,904)
Accounts payable and accrued current and non-current liabilities	(3,870)	(12,438)
Restructuring reserve	284	(11,129)
Net cash provided by operating activities	48,536	31,560
Investing Activities:
Acquisitions, net of cash acquired	(279,863)	(14,194)
Purchases of property, plant and equipment and other	(13,231)	(14,923)
Proceeds from the sale of CRM business franchise	186,682	0
Proceeds from sale of cost-method investment	0	3,192
Loans to equity method investees	0	(6,834)
Proceeds from asset sales	13,222	5,170
Other	0	(145)
Net cash used in investing activities	(93,190)	(27,734)
Financing Activities:
Change in short-term borrowing, net	(17,971)	(12,812)
Proceeds from short-term borrowing (maturities greater than 90 days)	240,000	20,000
Repayment of short-term borrowing (maturities greater than 90 days)	(190,000)	0
Repayment of long-term debt obligations	(12,240)	(11,306)
Proceeds from exercise of stock options	2,731	2,442
Payment of deferred consideration - acquisition of Caisson Interventional, LLC	(14,073)	0
Shares repurchased from employees for minimum tax withholding	(7,130)	(1,594)
Other	390	97
Net cash provided by (used in) financing activities	927	(3,367)
Effect of exchange rate changes on cash and cash equivalents	(2,508)	2,442
Net (decrease) increase in cash and cash equivalents	(46,235)	2,901
Cash and cash equivalents at beginning of period	93,615	39,789
Cash and cash equivalents at end of period	$ 47,380	$ 42,690

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Financial Statements	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Unaudited Condensed Consolidated Financial Statements	Note 1. Unaudited Condensed Consolidated Financial Statements Basis of Presentation The accompanying condensed consolidated financial statements of LivaNova as of, and for the three and six months ended June 30, 2018 and June 30, 2017 , have been prepared in accordance with U.S. GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying condensed consolidated balance sheet of LivaNova at December 31, 2017 has been derived from audited financial statements contained in our 2017 Form 10-K, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair statement of the operating results of LivaNova and its subsidiaries, for the three and six months ended June 30, 2018 and are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 . The financial information presented herein should be read in conjunction with the audited consolidated financial statements and notes thereto accompanying our 2017 Form 10-K. Sale of our Cardiac Rhythm Management Business Franchise We completed the sale of our Cardiac Rhythm Management (“CRM”) business franchise to MicroPort Cardiac Rhythm B.V. and MicroPort Scientific Corporation (the “CRM Sale”) on April 30, 2018 for total cash proceeds of $195.9 million , less cash transferred of $9.2 million , subject to certain closing adjustments. In conjunction with the CRM Sale, we entered into transition services agreements to provide certain support services for generally up to twelve months from the closing date of the sale. We previously concluded that the sale of CRM represents a strategic shift in our business that will have a major effect on future operations and financial results. As a result, we classified the operating results of CRM as discontinued operations in our condensed consolidated statements of income. The assets and liabilities of CRM are presented as assets or liabilities of discontinued operations in the condensed consolidated balance sheet at December 31, 2017 . Reclassification of Prior-Year Comparative Period Presentation We have reclassified certain prior period amounts for comparative purposes. These reclassifications did not have a material effect on our financial condition, results of operations or cash flows. To conform the presentation on the condensed consolidated statement of cash flows for the six months ended June 30, 2017 , to the presentation for the year ended December 31, 2017 in our 2017 Form 10-K, loans to cost and equity method investees of $6.8 million was reclassified to Investing Activities from Financing Activities. We reclassified $34.0 million to contingent consideration from other long-term liabilities at December 31, 2017 to conform to the presentation on the condensed consolidated balance sheet at June 30, 2018 . Significant Accounting Policies Our significant accounting policies are detailed in "Note 2: Basis of Presentation, Use of Accounting Estimates and Significant Accounting Policies" of our 2017 Form 10-K. On January 1, 2018, we adopted ASC Update (“ASU”) No 2014-09, Revenue from Contracts with Customers. Refer to “ Note 2. Revenue Recognition .” We elected the cumulative effect transition method; however, we recognized no cumulative effect to the opening balance of retained earnings because the impact on the timing of when revenue is recognized within our Cardiac Surgery segment, specifically related to heart-lung machines and preventative maintenance contracts on cardiopulmonary equipment, was insignificant. The timing of revenue recognition for products and related revenue streams within our Neuromodulation segment and discontinued operations did not change.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 2. Revenue Recognition We generate our revenue through contracts with customers that primarily consist of hospitals, healthcare institutions, distributors and other organizations. Revenue is measured based on consideration specified in a contract with a customer, and excludes amounts collected on behalf of third parties. We measure the consideration based upon the estimated amount to be received. The amount of consideration we ultimately receive varies depending upon the return terms, sales rebates, discounts, and other incentives that we may offer, which are accounted for as variable consideration when estimating the amount of revenue to recognize. The estimate of variable consideration requires significant judgment. We have historically experienced a low rate of product returns and the total dollar value of product returns has not been significant to our financial statements. We recognize revenue when a performance obligation is satisfied by transferring the control of a product or providing service to a customer. Some of our contracts include the purchase of multiple products and/or services. In such cases, we allocate the transaction price based upon the relative estimated stand-alone price of each product and/or service sold. We record state and local sales taxes net; that is, we exclude sales tax from revenue. Typically, our contracts do not have a significant financing component. We incur incremental commission fees paid to the sales force associated with the sale of products. We apply the practical expedient within ASC 606-10-50-22 and have elected to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset the entity would otherwise recognize is one year or less. As a result, no commissions are capitalized as contract costs at June 30, 2018 . The following is a description of the principal activities (separated by reportable segments) from which we generate our revenue. For more detailed information about our reportable segments including disaggregated revenue results by major product line and primary geographic markets, see “ Note 16. Geographic and Segment Information ”. Cardiac Surgery Products and Services The Cardiac Surgery (“CS”) segment has three primary product lines: cardiopulmonary products, heart valves and advanced circulatory support. Cardiopulmonary products include oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae and other related accessories. Heart valves include mechanical heart valves, tissue heart valves and related repair products. Technical services include installation, repair and maintenance of cardiopulmonary equipment under service contracts or upon customer request. Cardiopulmonary products may include performance obligations associated with assembly and installation of equipment. Accordingly, we allocate a portion of the sales prices to installation obligations and recognize that revenue when the service is provided. We recognize revenue for equipment and accessory product sales when control of the equipment or product passes to the customer. Heart valve revenue is recognized when control passes to the customer, usually at the point of surgery. Advanced circulatory support revenue, which represents our recently acquired TandemLife business, is principally derived from the sale of temporary life support product kits that can include a combination of pumps, oxygenators, and cannulae. Revenue is recognized when control passes to the customer, usually at the point of shipment. Technical service agreements generally provide for upfront payments in advance of rendering services or periodic billing over the contract term. Amounts billed in advance are deferred and recognized as revenue when the performance obligation is satisfied. Technical services are not a significant component of CS revenue and have been presented with the related equipment and accessories revenue. Neuromodulation Products Our Neuromodulation (“NM”) segment generates its revenue from the sale of neuromodulation therapy systems for the treatment of drug-resistant epilepsy, treatment-resistant depression and obstructive sleep apnea. The NM product line includes the VNS Therapy System, which consists of an implantable pulse generator, a lead that connects the generator to the vagus nerve, and other accessories. The NM product line also includes an implantable device for the treatment of obstructive sleep apnea that stimulates multiple tongue muscles via the hypoglossal nerve, which opens the airway while a patient is sleeping. We recognize revenue for product sales when control passes to the customer. Discontinued Operations: Cardiac Rhythm Management Products CRM generated revenue from the sale of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. CRM devices include high-voltage defibrillators and low-voltage pacemakers. We recognize revenue for product sales when control passes to the customer. Contract Balances Due to the nature of our products and services, revenue producing activities may result in contract assets and contract liabilities which are insignificant to our financial position and results of operations. These activities relate primarily to CS technical services contracts for short-term and multi-year service agreements. Contract assets are primarily comprised of unbilled revenues, which occur when a performance obligation has been completed, but not billed to the customer. Contract liabilities are made up of deferred revenue, which occurs when a customer pays for a service, before a performance obligation has been completed. Contract assets are included within “Prepaid expenses and other current assets” in the condensed consolidated balance sheets and were insignificant at June 30, 2018 and December 31, 2017 . As of June 30, 2018 and December 31, 2017 , contract liabilities of $5.1 million and $3.8 million , respectively, are included within “Accrued liabilities and other” and “Other long-term liabilities” in the condensed consolidated balance sheets.

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2018
Business Combinations [Abstract]
Business Combinations	Note 3. Business Combinations Caisson Interventional, LLC On May 2, 2017, we acquired the remaining 51% equity interests in Caisson Interventional, LLC ( “ Caisson”) for a purchase price of up to $72.0 million , net of $6.3 million of debt forgiveness, consisting of $18.0 million paid at closing, $14.4 million paid during the second quarter of 2018, and contingent consideration of up to $39.6 million to be paid on a schedule driven primarily by regulatory approvals and a sales-based earnout. Caisson is focused on the design, development and clinical evaluation of a novel transcatheter mitral valve replacement (“TMVR”) implant device with a fully transvenous delivery system for the treatment of mitral valve regurgitation. The purchase price allocation was finalized during the second quarter of 2018 and there were no adjustments to the preliminary purchase price allocation during the measurement period. We performed a quantitative impairment assessment, as of April 1, 2018, for the goodwill and in-process research and development assets arising from the Caisson acquisition. Based upon the assessment performed, we determined that the goodwill and the in-process research and development assets were not impaired. The quantitative impairment assessment was performed using management’s current estimate of future cash flows which are based on the expected timing of future regulatory approvals. A delay in the anticipated timing of these regulatory approvals or a change in management’s estimates could result in a fair value of the in-process research and development that is below its carrying amount. We will continue to monitor any changes in circumstances for indicators of impairment. ImThera Medical, Inc. On January 16, 2018, we acquired the remaining 86% outstanding interest in ImThera Medical, Inc. (“ImThera”) for cash consideration of up to $225 million . Cash of $78.3 million was paid at closing with the balance to be paid based on achievement of a certain regulatory milestone and a sales-based earnout. Headquartered in San Diego, California, ImThera manufactures an implantable device for the treatment of obstructive sleep apnea that stimulates multiple tongue muscles via the hypoglossal nerve, which opens the airway while a patient is sleeping. ImThera has a commercial presence on the European market, and an FDA pivotal study is ongoing in the U.S. ImThera is highly aligned with our Neuromodulation Business Franchise. The following table presents the acquisition date fair value of the consideration transferred and the fair value of our interest in ImThera prior to the acquisition (in thousands): Cash $ 78,332 Contingent consideration 112,744 Fair value of our interest in ImThera prior to the acquisition (1) 25,580 Fair value of consideration transferred $ 216,656 (1) The fair value of our previously-held interest in ImThera was determined based on the fair value of total consideration transferred and application of a discount for lack of control. As a result, we recognized a gain of $11.5 million for the fair value in excess of our carrying value of $14.1 million . The gain is reflected as “Gain on acquisitions” on our condensed consolidated statement of income for the six months ended June 30, 2018 . The following table presents the preliminary purchase price allocation at fair value for the ImThera acquisition including certain measurement period adjustments (in thousands): Initial Purchase Price Allocation Measurement Period Adjustments (1) Adjusted Purchase Price Allocation In-process research and development (2) $ 151,605 $ 10,677 $ 162,282 Developed technology 5,661 (5,661 ) — Goodwill 87,063 (4,467 ) 82,596 Deferred income tax liabilities, net (3) (27,980 ) (1,278 ) (29,258 ) Other assets and liabilities, net 836 200 1,036 Net assets acquired $ 217,185 $ (529 ) $ 216,656 (1) During the second quarter of 2018, measurement period adjustments were recorded based upon new information obtained about facts and circumstances that existed as of the acquisition date. (2) The fair value of in-process research and development ("IPR&D") was determined using the income approach, which is a valuation technique that provides a fair value estimate based on the market participant expectations of cash flows the asset would generate. The cash flows were discounted commensurate with the level of risk associated with the asset. The discount rates were developed after assigning a probability of success to achieving the projected cash flows based on the current stage of development, inherent uncertainty in reaching certain regulatory milestones and risks associated with commercialization of the product. The IPR&D amount is included in “Intangible assets, net” in the condensed consolidated balance sheet at June 30, 2018 . (3) The amount includes a provisional estimate for deferred tax assets acquired. Goodwill arising from the ImThera acquisition, which is not deductible for tax purposes, primarily represents the synergies anticipated between ImThera and our existing neuromodulation business. The assets acquired, including goodwill, are recognized in our Neuromodulation segment. During the second quarter of 2018, we determined that developments in the ImThera clinical trial will result in a minimum 12-month delay of regulatory approval. This delay constituted a triggering event that required evaluation of the in-process research and development asset for impairment. Based on the quantitative impairment evaluation, the in-process research and development asset was not impaired; however, a further delay or a change in management’s estimates could result in a fair value that is below the carrying amount for such an asset. We will continue to monitor any changes in circumstances for indicators of impairment. The results of the ImThera acquisition added $0.1 million and $0.2 million in revenue and $2.6 million and $3.6 million in operating losses during the three and six months ended June 30, 2018 , respectively. Additionally, we recognized ImThera acquisition-related expenses of approximately $0.2 million and $0.3 million for legal and valuation expenses during the three and six months ended June 30, 2018 , respectively. These expenses are included within “Selling, general and administrative” expenses in the condensed consolidated statement of income. Pro forma financial information assuming the ImThera acquisition had occurred as of the beginning of the calendar year prior to the year of acquisition was not material for disclosure purposes. The ImThera business combination involved contingent consideration arrangements composed of potential cash payments upon the achievement of a certain regulatory milestone and a sales-based earnout associated with sales of products covered by the purchase agreement. The sales-based earnout was valued using projected sales from our internal strategic plan. Both arrangements are Level 3 fair value measurements and include the following significant unobservable inputs (in thousands): ImThera Acquisition Fair value at January 16, 2018 Valuation Technique Unobservable Input Ranges Regulatory milestone-based payment $ 50,429 Discounted cash flow Discount rate 4.3% - 4.7% Probability of payment 85% - 95% Projected payment years 2020 - 2021 Sales-based earnout 62,315 Monte Carlo simulation Risk-adjusted discount rate 11.5% Credit risk discount rate 4.7% - 5.8% Revenue volatility 29.3% Probability of payment 85% - 95% Projected years of earnout 2020 - 2025 $ 112,744 TandemLife On April 4, 2018, we acquired CardiacAssist, Inc., doing business as TandemLife (“TandemLife”) for cash consideration of up to $250 million . Cash of $204 million was paid at closing with up to $50 million in contingent consideration based on achieving regulatory milestones. TandemLife, headquartered in Pittsburgh, Pennsylvania, is focused on the delivery of leading-edge temporary life support systems, including cardiopulmonary and respiratory support solutions. TandemLife complements our Cardiac Surgery portfolio, and expands our existing line of cardiopulmonary products. The following table presents the acquisition date fair value of the consideration transferred (in thousands): Cash $ 203,671 Contingent consideration 40,190 Fair value of consideration transferred $ 243,861 The following table presents the preliminary purchase price allocation at fair value for the TandemLife acquisition (in thousands): In-process research and development (1) (2) (3) $ 110,977 Trade names (1) 11,539 Developed technology (1) 6,387 Goodwill 118,917 Inventory 10,296 Other assets and liabilities, net 3,632 Deferred income tax liabilities, net (3) (17,887 ) Net assets acquired $ 243,861 (1) The amounts above are included in “Intangible assets, net” in the condensed consolidated balance sheet at June 30, 2018 . Trade names and developed technology are amortized over remaining useful lives of 15 and 2 years, respectively. (2) The fair value of in-process research and development ("IPR&D") was determined using the income approach, which is a valuation technique that provides a fair value estimate based on the market participant expectations of cash flows the asset would generate. The cash flows were discounted commensurate with the level of risk associated with the asset. The discount rates were developed after assigning a probability of success to achieving the projected cash flows based on the current stage of development, inherent uncertainty in reaching certain regulatory milestones and risks associated with commercialization of the product. (3) The amounts include provisional estimates based on the information available as of the acquisition date. The Company is gathering additional information necessary to finalize the estimated fair values for deferred tax assets acquired and IPR&D. Goodwill arising from the TandemLife acquisition, which is not deductible for tax purposes, primarily represents the synergies anticipated between TandemLife and our existing cardiac surgery business. The assets acquired, including goodwill, are recognized in our Cardiac Surgery segment. The results of the TandemLife acquisition added $6.0 million in revenue and $6.1 million in operating losses during each of the three and six months ended June 30, 2018. Additionally, we recognized TandemLife acquisition-related expenses of approximately $1.6 million and $1.9 million for legal and valuation expenses during the three and six months ended June 30, 2018 , respectively. These expenses are included within “Selling, general and administrative” expenses in the condensed consolidated statement of income. Pro forma financial information assuming the TandemLife acquisition had occurred as of the beginning of the calendar year prior to the year of acquisition was not material for disclosure purposes. The TandemLife business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs (in thousands): TandemLife Acquisition Fair value at April 4, 2018 Valuation Technique Unobservable Input Ranges Regulatory milestone-based payments $ 40,190 Discounted cash flow Discount rate 4.2% - 4.8% Probability of payments 75% - 95% Projected payment years 2019 - 2020

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 4. Discontinued Operations In November 2017, we concluded that the sale of CRM represented a strategic shift in our business that would have a major effect on future operations and financial results. As a result, we classified the operating results of CRM as discontinued operations in our condensed consolidated statements of income for all the periods presented in this Quarterly Report on Form 10-Q. The assets and liabilities of CRM are presented as assets or liabilities of discontinued operations in the condensed consolidated balance sheets at December 31, 2017 . We completed the CRM Sale on April 30, 2018 for total cash proceeds of $195.9 million , less cash transferred of $9.2 million , subject to certain customary closing adjustments. In conjunction with the sale, we entered into transition services agreements to provide certain support services for generally up to twelve months from the closing date of the sale. The services include, among others, accounting, information technology, human resources, quality assurance, regulatory affairs, supply chain, clinical affairs and customer support. During the six months ended June 30, 2018 , we recognized income of $0.9 million for providing these services. Income recognized related to the transition services agreements is recorded as a reduction to the related expenses in the associated expense line items in the condensed consolidated statements of income. The following table represents assets and liabilities of CRM presented as assets and liabilities of discontinued operations in the condensed consolidated balance sheet: December 31, 2017 Accounts receivable, net $ 64,684 Inventories 54,097 Prepaid taxes 14,725 Prepaid and other assets 3,498 Property, plant and equipment, net 12,104 Deferred tax assets, net 2,517 Investments 6,098 Intangible assets, net 92,966 Assets of discontinued operations $ 250,689 Accounts payable 26,501 Accrued liabilities and other 7,669 Taxes payable 5,084 Accrued employee compensation and benefits 30,753 Deferred income taxes liability 8,068 Liabilities of discontinued operations $ 78,075 The following table represents the financial results of CRM presented as net (loss) income from discontinued operations in the condensed consolidated statements of income: Three Months Ended June 30, Six Months Ended June 30, 2018 (1) 2017 2018 (1) 2017 Revenues $ 27,206 $ 65,544 $ 87,313 $ 123,824 Cost of sales 10,391 24,800 32,529 46,285 Gross profit 16,815 40,744 54,784 77,539 Selling, general and administrative expenses 15,073 25,960 46,899 50,997 Research and development 5,929 9,118 17,210 18,377 Merger and integration expenses — 10 — 32 Restructuring expenses — (1,479 ) 651 (1,359 ) Amortization of intangibles — 3,565 — 7,019 Revaluation gain on assets and liabilities held for sale — — (1,213 ) — Loss on sale of CRM 214 — 214 — Total operating expenses 21,216 37,174 63,761 75,066 Operating (loss) income from discontinued operations (4,401 ) 3,570 (8,977 ) 2,473 Foreign exchange and other (losses) gains (67 ) (402 ) 12 (172 ) (Loss) income from discontinued operations, before tax (4,468 ) 3,168 (8,965 ) 2,301 Income tax (benefit) expense (6 ) 54 (1,165 ) 54 Losses from equity method investments — (1,295 ) (1,211 ) (2,384 ) Net (loss) income from discontinued operations (1) $ (4,462 ) $ 1,819 $ (9,011 ) $ (137 ) (1) CRM financial results for the three and six month periods ended June 30, 2018 include activity through the close of the sale on April 30, 2018. Cash flows attributable to our discontinued operations are included in our condensed consolidated statements of cash flows. For the six months ended June 30, 2018 and 2017, CRM’s capital expenditures were $0.9 million and $2.4 million , respectively and stock-based compensation expense was $2.1 million and $0.3 million , respectively. For the six months ended June 30, 2017 depreciation and amortization was $9.9 million .

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring	Note 5. Restructuring Our 2015 and 2016 Reorganization Plans (the “Plans”) were initiated October 2015 and March 2016, respectively, in conjunction with the completion of the merger of Cyberonics, Inc. and Sorin S.p.A. in October 2015. We initiated these plans to leverage economies of scale, streamline distribution and logistics and strengthen operational and administrative effectiveness in order to reduce overall costs. Costs associated with these plans are reported as ‘Restructuring expenses’ in our operating results in the condensed consolidated statements of income. In March 2017, we committed to a plan to sell our Suzhou Industrial Park facility in Shanghai, China. As a result of this exit plan we recorded an impairment of the building and equipment of $4.6 million and accrued $0.5 million of additional costs, primarily related to employee severance, during the six months ended June 30, 2017 . The land, building and equipment were recorded as Assets held for sale on the condensed consolidated balance sheet as of December 31, 2017. We completed the sale of the Suzhou facility in April 2018 and received cash proceeds from the sale of $13.3 million . The following table presents the Plans’ accruals, inventory obsolescence and other reserves, recorded in connection with the Reorganization Plans including the balances and activity related to the discontinued operations, (in thousands): Employee Severance and Other Termination Costs Other Total Balance at December 31, 2017 $ 3,889 $ 2,625 $ 6,514 Charges 2,544 464 3,008 Cash payments and adjustments (5,431 ) (470 ) (5,901 ) Balance at June 30, 2018 $ 1,002 $ 2,619 $ 3,621 The following table presents restructuring expense by reportable segment, with discontinued operations included (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Cardiac Surgery (1) $ 398 $ 501 $ 1,739 $ 6,503 Neuromodulation 11 (233 ) 17 439 Other 67 2,329 601 5,685 Restructuring expense from continuing operations 476 2,597 2,357 12,627 Discontinued operations — (1,479 ) 651 (1,359 ) Total $ 476 $ 1,118 $ 3,008 $ 11,268 (1) Cardiac Surgery restructuring expense for the six months ended June 30, 2017 included building and equipment impairment and additional costs of $5.1 million related to the Suzhou, China facility exit plan.

Product Remediation Liability

Product Remediation Liability	6 Months Ended
	Jun. 30, 2018
Environmental Remediation Obligations [Abstract]
Product Remediation Liability	Note 6. Product Remediation Liability On December 29, 2015, we received an FDA Warning Letter (the “Warning Letter”) alleging certain violations of FDA regulations applicable to medical device manufacturing at our Munich, Germany and Arvada, Colorado facilities. On October 13, 2016, the Centers for Disease Control and Prevention (“CDC”) and FDA separately released safety notifications regarding the 3T Heater-Cooler devices in response to which we issued a Field Safety Notice Update for U.S. users of 3T Heater-Cooler devices to proactively and voluntarily contact facilities to facilitate implementation of the CDC and FDA recommendations. At December 31, 2016, we recognized a liability for a product remediation plan related to our 3T Heater-Cooler device (“3T device”). The remediation plan we developed consists primarily of a modification of the 3T device design to include internal sealing and the addition of a vacuum system to new and existing devices. These changes are intended to address regulatory actions and to reduce further the risk of possible dispersion of aerosols from 3T devices in the operating room. We concluded that it was probable that a liability had been incurred upon management’s approval of the plan and the commitments made by management to various regulatory authorities globally in November and December 2016, and furthermore, the cost associated with the plan was reasonably estimable. The deployment of this solution for commercially distributed devices has been dependent upon final validation and verification of the design changes and approval or clearance by regulatory authorities worldwide, including FDA clearance in the U.S. It is reasonably possible that our estimate of the remediation liability could materially change in future periods due to the various significant assumptions involved such as customer behavior, market reaction and the timing of approvals or clearance by regulatory authorities worldwide. In April 2017, we obtained CE Mark in Europe for the design change of the 3T device and in May 2017 we completed our first vacuum and sealing upgrade on a customer-owned device. We are currently implementing the vacuum and sealing upgrade program in as many countries as possible throughout 2018 and beyond until all devices are upgraded. As part of the remediation plan, we also intend to perform a no-charge deep disinfection service (deep cleaning service) for 3T device users as we receive the required regulatory approvals. On April 12, 2018, the FDA agreed to allow us to move forward with the deep cleaning service in the U.S., adding to the growing list of countries around the world in which we offer this service. Finally, we are continuing to offer the loaner program for 3T devices, initiated in the fourth quarter of 2016, to provide existing 3T device users with a new loaner 3T device at no charge pending regulatory approval and implementation of the vacuum system addition and deep disinfection service worldwide. This loaner program began in the U.S. and is being made available progressively on a global basis, prioritizing and allocating devices to 3T device users based on pre-established criteria. Changes in the carrying amount of the product remediation liability are as follows (in thousands): Balance at December 31, 2017 $ 27,546 Remediation activity (7,272 ) Effect of changes in foreign currency exchange rates (557 ) Balance at June 30, 2018 (1) $ 19,717 (1) At June 30, 2018 , the product remediation liability balance is held within ‘Accrued liabilities and other’ and ‘Other long-term liabilities’ in the condensed consolidated balance sheet. For further information, please refer to “ Note 11. Commitments and Contingencies .” At this stage, we have recognized no liability with respect to any lawsuits related to the 3T device and our related legal costs are expensed as incurred.

Investments

Investments	6 Months Ended
	Jun. 30, 2018
Investments [Abstract]
Investments	Note 7. Investments Cost-Method Investments Our cost-method investments are included in “Investments” in the condensed consolidated balance sheets and consist of our equity positions in the following privately-held companies (in thousands): June 30, 2018 December 31, 2017 Respicardia Inc. (1) $ 17,705 $ 17,422 ImThera Medical, Inc. (2) — 12,900 Rainbow Medical Ltd. (3) 1,140 1,172 MD Start II (4) 1,164 1,199 Highlife S.A.S. (5) 1,104 — Other 17 17 $ 21,130 $ 32,710 (1) Respicardia Inc. (“Respicardia”) is a privately funded U.S. company developing an implantable device designed to restore a more natural breathing pattern during sleep in patients with central sleep apnea ("CSA") by transvenously stimulating the phrenic nerve. We have a loan outstanding to Respicardia with a carrying amount of $0.5 million , as of June 30, 2018 , which is included in “Prepaid expenses and other current assets” in the condensed consolidated balance sheet. (2) On January 16, 2018, we acquired the remaining outstanding interests in ImThera. Refer to “ Note 3. Business Combinations ”. (3) Rainbow Medical Ltd. is a private Israeli venture capital company that seeds and grows companies developing medical devices in a diverse range of medical fields. (4) MD Start II is a private venture capital collaboration for the development of medical device technology in Europe. (5) Due to an additional investment by a third party during the three months ended June 30, 2018 , our equity interest in Highlife S.A.S. (“Highlife”) decreased to 17.5% from 24.6% . We determined that we no longer had significant influence over Highlife and it is now considered a cost method investment. The carrying amount of our equity-method investment in Highlife was $1.8 million at December 31, 2017 .

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8. Fair Value Measurements We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers between Level 1, Level 2, or Level 3 during the six months ended June 30, 2018 . Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table provides information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands): Fair Value as of June 30, 2018 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Liabilities: Derivative liabilities - designated as cash flow hedges (foreign currency exchange rate "FX") $ 1,209 $ — $ 1,209 $ — Derivative liabilities - designated as cash flow hedges (interest rate swaps) 1,221 — 1,221 — Derivative liabilities - freestanding instruments (FX) 827 — 827 — Contingent consideration (1) 181,133 — — 181,133 $ 184,390 $ — $ 3,257 $ 181,133 Fair Value as of December 31, 2017 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - freestanding instruments (FX) $ 519 $ — $ 519 $ — $ 519 $ — $ 519 $ — Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 460 $ — $ 460 $ — Derivative liabilities - designated as cash flow hedges (interest rate swaps) 1,585 — 1,585 — Contingent consideration (1) 33,973 — — 33,973 $ 36,018 $ — $ 2,045 $ 33,973 (1) The contingent consideration liability represents contingent payments related to five completed acquisitions: Cellplex PTY Ltd., Inversiones Drilltex SAS, Caisson, ImThera and TandemLife. See the table below for additional information. Our recurring fair value measurements, using significant unobservable inputs (Level 3), relate solely to our contingent consideration liability. The following table provides a reconciliation of the beginning and ending balance of the contingent consideration liability (in thousands): Total contingent consideration liability at December 31, 2017 $ 33,973 Purchase price - ImThera contingent consideration 112,744 Purchase price - TandemLife contingent consideration 40,190 Payments (196 ) Changes in fair value (1) (5,546 ) Effect of changes in foreign currency exchange rates (32 ) Total contingent consideration liability at June 30, 2018 181,133 Less current portion of contingent consideration liability at June 30, 2018 2,684 Long-term portion of contingent consideration liability at June 30, 2018 $ 178,449 (1) Includes a decrease of $6.1 million due to the delay in the timing of anticipated regulatory approval for ImThera. See “ Note 3. Business Combinations ” for additional discussion.

Financing Arrangements

Financing Arrangements	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Financing Arrangements	Note 9. Financing Arrangements The outstanding principal amount of long-term debt (in thousands, except interest rates): June 30, 2018 December 31, 2017 Maturity Interest Rate European Investment Bank (1) $ 58,213 $ 69,893 June 2021 0.95 % Mediocredito Italiano (2) 8,406 9,118 December 2023 0.50% - 3.10% Banca del Mezzogiorno (3) 4,137 5,499 December 2019 0.50% - 3.15% Region Wallonne 756 845 December 2023 and June 2033 0.00% - 2.45% Mediocredito Italiano - mortgages and other 536 997 September 2021 and September 2026 0.80% - 1.30% Bpifrance (ex-Oséo) — 1,450 — 2.58 % Total long-term facilities 72,048 87,802 Less current portion of long-term debt 21,635 25,844 Total long-term debt $ 50,413 $ 61,958 (1) The European Investment Bank (“EIB”) loan was obtained in July 2014 to support product development projects. The interest rate for the EIB loan is reset by the lender each quarter based on the Euribor. Interest payments are paid quarterly and principal payments are paid semi-annually. (2) We obtained the Mediocredito Italiano Bank loan in July 2016 as part of the Fondo Innovazione Teconologica program implemented by the Italian Ministry of Education. (3) The Banca del Mezzogiorno loan was obtained in January 2015 to support R&D projects as a part of the Large Strategic Project program of the Italian Ministry of Education. Revolving Credit The outstanding principal amount of our short-term unsecured revolving credit agreements and other agreements with various banks was $89.0 million and $58.2 million , at June 30, 2018 and December 31, 2017 , respectively, with interest rates ranging from 0.1% to 9.3% and loan terms ranging from one day to 180 days . On April 10, 2018, we entered into an amendment and restatement agreement with Barclays Bank PLC amending the revolving facility agreement originally dated October 21, 2016 (the “Amendment”). The Amendment increases the borrowing capacity under the facility from $40.0 million to $70.0 million and extends the term of the facility one year, terminating October 20, 2019. Borrowings under the facility bear interest at a rate of LIBOR plus 0.85% . At June 30, 2018 this facility is fully utilized. In connection with the CRM sale, the borrowing capacity under our June 2017 finance contract with the European Investment Bank decreased from €100.0 million (approximately $116.4 million ) to €90.0 million (approximately $104.8 million ) and the availability for drawdowns was extended through December 31, 2020. Bridge Facility Agreement In connection with the April 2018 acquisition of TandemLife, LivaNova entered into a bridge facility agreement (the “Bridge Facility Agreement”) providing a term loan facility with the aggregate principal amount of $190.0 million . On April 3, 2018, we borrowed $190.0 million under the Bridge Facility Agreement to facilitate the initial payment for our acquisition of TandemLife. We used the proceeds from the sale of the CRM business franchise to repay the borrowings under the Bridge Facility Agreement in full during the second quarter of 2018.

Derivatives and Risk Management

Derivatives and Risk Management	6 Months Ended
	Jun. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Risk Management	Note 10. Derivatives and Risk Management Due to the global nature of our operations, we are exposed to foreign currency exchange rate fluctuations. In addition, due to certain loans with floating interest rates, we are also subject to the impact of changes in interest rates on our interest payments. We enter into foreign currency exchange rate (“FX”) derivative contracts and interest rate swap contracts to reduce the impact of foreign currency rate and interest rate fluctuations on earnings and cash flow. We measure all outstanding derivatives each period end at fair value and report the fair value as either financial assets or liabilities in the condensed consolidated balance sheets. We do not enter into derivative contracts for speculative purposes. At inception of the contract, the derivative is designated as either a freestanding derivative or a hedge. Derivatives that are not designated as hedging instruments are referred to as freestanding derivatives with changes in fair value included in earnings. If the derivative qualifies for hedge accounting, depending on the nature of the hedge and hedge effectiveness, changes in the fair value of the derivative will either be recognized immediately in earnings or recorded in accumulated other comprehensive income (“AOCI”) until the hedged item is recognized in earnings upon settlement/termination. FX derivative gains and losses in AOCI are reclassified to the condensed consolidated statements of income as shown in the tables below and interest rate swap gains and losses in AOCI are reclassified to interest expense in the condensed consolidated statements of income. We evaluate hedge effectiveness at inception and on an ongoing basis. If a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is recorded in earnings. Cash flows from derivative contracts are reported as operating activities in the condensed consolidated statements of cash flows. Freestanding Derivative FX Contracts The gross notional amount of FX derivative contracts, not designated as hedging instruments, outstanding at June 30, 2018 and December 31, 2017 was $256.0 million and $231.9 million , respectively. These derivative contracts are designed to offset the FX effects in earnings of various intercompany loans, our EIB loan, and trade receivables. We recorded net losses for these freestanding derivatives of $4.1 million and $5.4 million for the three months ended June 30, 2018 and June 30, 2017 , respectively and net losses of $11.7 million and $7.2 million for the six months ended June 30, 2018 and June 30, 2017 , respectively. The net losses are included in “ Foreign exchange and other (losses) gains ” in the condensed consolidated statements of income. Cash Flow Hedges Notional amounts of open derivative contracts designated as cash flow hedges (in thousands): Description of Derivative Contract June 30, 2018 December 31, 2017 FX derivative contracts to be exchanged for British Pounds $ 11,655 $ 16,847 FX derivative contracts to be exchanged for Japanese Yen 22,122 32,302 FX derivative contracts to be exchanged for Canadian Dollars 15,779 16,494 FX derivative contracts to be exchanged for Euros 38,581 — Interest rate swap contracts 46,570 55,965 $ 134,707 $ 121,608 After-tax net loss associated with derivatives designated as cash flow hedges recorded in the ending balance of AOCI and the amount expected to be reclassified to earnings in the next twelve months (in thousands): Description of Derivative Contract June 30, 2018 Amount Expected to be Reclassified to Earnings in Next 12 Months FX derivative contracts $ (1,011 ) $ (1,011 ) Interest rate swap contracts (253 ) (64 ) $ (1,264 ) $ (1,075 ) Pre-tax gains (losses) for derivative contracts designated as cash flow hedges recognized in Other Comprehensive Income (Loss) (“OCI”) and the amount reclassified to earnings from AOCI (in thousands): Three Months Ended June 30, 2018 2017 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other gains (losses) $ (25 ) $ (1,358 ) $ (755 ) $ (532 ) FX derivative contracts SG&A — 549 — 544 Interest rate swap contracts Interest expense — (17 ) — 543 $ (25 ) $ (826 ) $ (755 ) $ 555 Six Months Ended June 30, 2018 2017 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Gains Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other gains (losses) $ 189 $ (512 ) $ (7,587 ) $ (5,210 ) FX derivative contracts SG&A — 1,174 — 1,354 Interest rate swap contracts Interest expense — (17 ) — 212 $ 189 $ 645 $ (7,587 ) $ (3,644 ) The following tables present the fair value on a gross basis, and the location of, derivative contracts reported in the condensed consolidated balance sheets (in thousands): June 30, 2018 Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Interest rate swap contracts Accrued liabilities $ 683 Interest rate swap contracts Other long-term liabilities 538 FX derivative contracts Accrued liabilities 1,209 Total derivatives designated as hedging instruments 2,430 Derivatives Not Designated as Hedging Instruments FX derivative contracts Accrued liabilities 827 Total derivatives not designated as hedging instruments 827 Total derivatives $ 3,257 December 31, 2017 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) Interest rate swap contracts Prepaid expenses and other current assets $ — Accrued liabilities $ 834 Interest rate swap contracts Other assets — Other long-term liabilities 751 FX derivative contracts Prepaid expenses and other current assets — Accrued liabilities 460 Total derivatives designated as hedging instruments — 2,045 Derivatives Not Designated as Hedging Instruments FX derivative contracts Prepaid expenses and other current assets 519 Accrued liabilities — Total derivatives not designated as hedging instruments 519 — Total derivatives $ 519 $ 2,045 (1) For the classification of inputs used to evaluate the fair value of our derivatives, refer to “ Note 8. Fair Value Measurements .”

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11. Commitments and Contingencies FDA Warning Letter On December 29, 2015, the FDA issued a Warning Letter alleging certain violations of FDA regulations applicable to medical device manufacturers at our Munich, Germany and Arvada, Colorado facilities. The FDA inspected the Munich facility from August 24, 2015 to August 27, 2015 and the Arvada facility from August 24, 2015 to September 1, 2015. On August 27, 2015, the FDA issued a Form 483 identifying two observed non-conformities with certain regulatory requirements at the Munich facility. We did not receive a Form 483 in connection with the FDA’s inspection of the Arvada facility. Following the receipt of the Form 483, we provided written responses to the FDA describing corrective and preventive actions that were underway or to be taken to address the FDA’s observations at the Munich facility. The Warning Letter responded in part to our responses and identified other alleged violations related to the manufacture of our 3T device that were not previously included in the Form 483. The Warning Letter further stated that our 3T devices and other devices we manufactured at our Munich facility are subject to refusal of admission into the U.S. until resolution of the issues set forth by the FDA in the Warning Letter. The FDA has informed us that the import alert is limited to the 3T devices, but that the agency reserves the right to expand the scope of the import alert if future circumstances warrant such action. The Warning Letter did not request that existing users cease using the 3T device, and manufacturing and shipment of all of our products other than the 3T device remain unaffected by the import limitation. To help clarify these issues for current customers, we issued an informational Customer Letter in January 2016 and that same month agreed with the FDA on a process for shipping 3T devices to existing U.S. users pursuant to a certificate of medical necessity program. Finally, the Warning Letter stated that premarket approval applications for Class III devices to which certain Quality System regulation deviations identified in the Warning Letter are reasonably related will not be approved until the violations have been corrected; however, this restriction applies only to the Munich and Arvada facilities, which do not manufacture or design devices subject to Class III premarket approval. We continue to work diligently to remediate the FDA’s inspectional observations for the Munich facility, as well as the additional issues identified in the Warning Letter. We take these matters seriously and intend to respond timely and fully to the FDA’s requests. CDC and FDA Safety Communications and Company Field Safety Notice Update On October 13, 2016, the CDC and the FDA separately released safety notifications regarding the 3T devices. The CDC’s Morbidity and Mortality Weekly Report (“MMWR”) and Health Advisory Notice (“HAN”) reported that tests conducted by CDC and its affiliates indicate that there appears to be genetic similarity between both patient and 3T device strains of the non-tuberculous mycobacterium (“NTM”) bacteria M. chimaera isolated in hospitals in Iowa and Pennsylvania. Citing the geographic separation between the two hospitals referenced in the investigation, the report asserts that 3T devices manufactured prior to August 18, 2014 could have been contaminated during the manufacturing process. The CDC’s HAN and FDA’s Safety Communication, issued contemporaneously with the MMWR report, each assess certain risks associated with 3T devices and provide guidance for providers and patients. The CDC notification states that the decision to use the 3T device during a surgical operation is to be taken by the surgeon based on a risk approach and on patient need. Both the CDC’s and FDA’s communications confirm that 3T devices are critical medical devices and enable doctors to perform life-saving cardiac surgery procedures. Also on October 13, 2016, in response to the Warning Letter and CDC’s HAN and FDA’s Safety Communication, we issued a Field Safety Notice Update for U.S. users of 3T devices to proactively and voluntarily contact facilities to aid in implementation of the CDC and FDA recommendations. In the fourth quarter of 2016, we initiated a program to provide existing 3T device users with a new loaner 3T device at no charge pending regulatory approval and implementation of additional risk mitigation strategies worldwide. This loaner program began in the U.S. and is being made available progressively on a global basis, prioritizing and allocating devices to 3T device users based on pre-established criteria. We anticipate that this program will continue until we are able to address customer needs through a broader solution that includes implementation of one or more of the risk mitigation strategies currently under review with regulatory agencies. We are also currently implementing a vacuum and sealing upgrade program in as many countries as possible throughout 2018 and beyond until all devices are upgraded. Furthermore, we intend to perform a no-charge deep disinfection service (deep cleaning service) for 3T device users as we receive the required regulatory approvals. On April 12, 2018, the FDA agreed to allow us to move forward with the deep cleaning service in the U.S. adding to the growing list of countries around the world in which we offer this service. On December 31, 2016, we recognized a liability for our product remediation plan related to our 3T device. We concluded that it was probable that a liability had been incurred upon management’s approval of the plan and the commitments made by management to various regulatory authorities globally in November and December 2016, and furthermore, the cost associated with the plan was reasonably estimable. At June 30, 2018 , the product remediation liability was $19.7 million . Refer to “ Note 6. Product Remediation Liability ” for additional information. Litigation Product Liability The Company is currently involved in litigation involving our 3T device. The litigation includes a class action complaint in the U.S. District Court for the Middle District of Pennsylvania, federal multi-district litigation in the U.S. District Court for the Middle District of Pennsylvania, various U.S. state court cases and cases in jurisdictions outside the U.S. As of July 31, 2018, we are involved in approximately 135 claims worldwide, with the majority of the claims in various federal or state courts throughout the United States. The complaints generally seek damages and other relief based on theories of strict liability, negligence, breach of express and implied warranties, failure to warn, design and manufacturing defect, fraudulent and negligent misrepresentation/concealment, unjust enrichment, and violations of various state consumer protection statutes. The class action consists of all Pennsylvania residents who underwent open heart surgery at WellSpan York Hospital and Penn State Milton S. Hershey Medical Center between 2011 and 2015 and who currently are asymptomatic for NTM infection. Members of the class seek declaratory relief that the 3T devices are defective and unsafe for intended uses, medical monitoring, damages, and attorneys’ fees. LivaNova has filed a petition for permission to appeal the class certification order with the U.S. Court of Appeals for the Third Circuit. We have not recognized an expense related to damages in connection with these matters because any potential loss is not currently probable or reasonably estimable. In addition, we cannot reasonably estimate a range of potential loss, if any, that may result from these matters. Civil Investigative Demand On May 31, 2017, the Company received a Civil Investigative Demand (“CID”) from the US Attorney’s Office for the Northern District of Georgia. The CID requested, and we have provided, certain documents relating to the sales and marketing of VNS devices and related products in the State of Georgia. We have not recognized an expense related to this matter because any potential loss is not currently probable or reasonably estimable. In addition we cannot reasonably estimate a range of potential loss, if any, that may result from this matter. Environmental Liability SNIA Litigation Our subsidiary, Sorin S.p.A. (“Sorin”) was created as a result of a spin-off (the “Sorin spin-off”) from SNIA S.p.A. (“SNIA”) in January, 2004. SNIA subsequently became insolvent and the Italian Ministry of the Environment and the Protection of Land and Sea (the “Italian Ministry of the Environment”), sought compensation from SNIA in an aggregate amount of approximately $4 billion for remediation costs relating to the environmental damage at chemical sites previously operated by SNIA’s other subsidiaries. In September 2011 and July 2014, the Bankruptcy Court of Udine and the Bankruptcy Court of Milan held (in proceedings to which we are not parties) that the Italian Ministry of the Environment and other Italian government agencies (the “Public Administrations”) were not creditors of either SNIA or its subsidiaries in connection with their claims in the Italian insolvency proceedings. The Public Administrations appealed and in January 2016, the Court of Udine rejected the appeal. The Public Administrations have also appealed that decision. In January 2012, SNIA filed a civil action against Sorin in the Civil Court of Milan asserting joint liability of a parent and a spun-off company. On April 1, 2016, the Court of Milan dismissed all legal actions of SNIA and of the Public Administrations further requiring the Public Administrations to pay Sorin approximately $340,000 for legal fees. The Public Administrations appealed the 2016 Decision to the Court of Appeal of Milan and a final decision is pending. We have not recognized an expense in connection with this matter because any potential loss is not currently probable or reasonably estimable. In addition, we cannot reasonably estimate a range of potential loss, if any, that may result from this matter. Environmental Remediation Order On July 28, 2015, Sorin received an administrative order (the “Remediation Order”) from the Italian Ministry of the Environment directing prompt commencement of environmental remediation at the chemical sites previously operated by SNIA’s other subsidiaries. We challenged the Remediation Order before the Administrative Court of Lazio in Rome (the “TAR”), and the TAR annulled the Remediation Order. The Italian Ministry of the Environment appealed to the Administrative Court of Appeal. A hearing occurred on June 14, 2018, and a final decision is pending. We have not recognized an expense in connection with this matter because any potential loss is not currently probable or reasonably estimable. In addition, we cannot reasonably estimate a range of potential loss, if any, that may result from this matter. Opposition to Merger Proceedings On July 28, 2015, the Public Administrations filed an opposition proceeding to the merger between Sorin and Cyberonics, Inc. (the “Merger”), before the Commercial Courts of Milan. The Court authorized the Merger and the Public Administrations did not appeal this decision. The proceeding then continued as a civil case, with the Public Administration seeking damages. The Commercial Court of Milan delivered a decision in October 2016, fully rejecting the Public Administration’s request and awarding us approximately $480,000 in damages for frivolous litigation and legal fees. The Public Administrations appealed to the Court of Appeal of Milan. On May 15, 2018, the Court of Appeal of Milan confirmed its decision authorizing the Merger, but reduced the penalty of $480,000 in damages for frivolous litigation and legal fees to $58,000 for legal fees. The Public Administrations subsequently filed an appeal with the Supreme Court against the decision of the Court of Appeal of Milan. We have not recognized an expense in connection with this matter because any potential loss is not currently probable or reasonably estimable. In addition, we cannot reasonably estimate a range of potential loss, if any, that may result from this matter. Patent Litigation On May 11, 2018, a non-practicing entity (NPE) filed a complaint in the Southern District of Texas asserting that the VNS Therapy System, when used with the SenTiva Model 1000 generator, infringes the claims of a single U.S. patent owned by the NPE. The NPE requests damages that include a royalty, costs, interest, and attorneys’ fees. We have not recognized an expense in connection with this matter because any potential loss is not currently probable or reasonably estimable. In addition, we cannot reasonably estimate a range of potential loss, if any, that may result from this matter. Tax Litigation In a tax audit report received October 30, 2009, the Regional Internal Revenue Office of Lombardy (the “Internal Revenue Office”) informed Sorin Group Italia S.r.l. that, among several issues, it was disallowing in part (for a total of €102.6 million (approximately $119.5 million ), related to tax years 2002 through 2006) a tax-deductible write down of the investment in the U.S. company, Cobe Cardiovascular Inc., which Sorin Group Italia S.r.l. recognized in 2002 and deducted in five equal installments, beginning in 2002. In December 2009, the Internal Revenue Office issued notices of assessment for 2002, 2003 and 2004. The assessments for 2002 and 2003 were automatically voided for lack of merit. In December 2010 and October 2011, the Internal Revenue Office issued notices of assessment for 2005 and 2006, respectively. We challenged all three notices of assessment (for 2004, 2005 and 2006) before the relevant Provincial Tax Courts. The preliminary challenges filed for 2004, 2005 and 2006 were denied at the first jurisdictional level. We appealed these decisions. The appeal submitted against the first-level decision for 2004 was successful. The Internal Revenue Office appealed this second-level decision to the Italian Supreme Court (Corte di Cassazione) on February 3, 2017. The Italian Supreme Court’s decision is pending. The appeals submitted against the first-level decisions for 2005 and 2006 were rejected. We appealed these adverse decisions to the Italian Supreme Court, where the matters are still pending. In November 2012, the Internal Revenue Office served a notice of assessment for 2007, and in July 2013, served a notice of assessment for 2008. In these matters the Internal Revenue Office claims an increase in taxable income due to a reduction (similar to the previous notices of assessment for 2004, 2005 and 2006) of the losses reported by Sorin Group Italia S.r.l. for the 2002, 2003 and 2004 tax periods, and subsequently utilized in 2007 and 2008. We challenged both notices of assessment. The Provincial Tax Court of Milan has stayed its decision for years 2007 and 2008 pending resolution of the litigation regarding years 2004, 2005, and 2006. The total amount of losses in dispute is €62.6 million (approximately $72.9 million ). We have continuously reassessed our potential exposure in these matters, taking into account the recent, and generally adverse, trend to Italian taxpayers in this type of litigation. Although we believe that our defensive arguments are strong, noting the adverse trend in some of the court decisions, we have recognized a reserve for an uncertain tax position of €17.0 million (approximately $19.7 million ). Other Matters Additionally, we are the subject of various pending or threatened legal actions and proceedings that arise in the ordinary course of our business. These matters are subject to many uncertainties and outcomes that are not predictable and that may not be known for extended periods of time. Since the outcome of these matters cannot be predicted with certainty, the costs associated with them could have a material adverse effect on our consolidated net income, financial position or liquidity.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 12. Stockholders’ Equity Comprehensive income The table below presents the change in each component of AOCI, net of tax, and the reclassifications out of AOCI into net income for the six months ended June 30, 2018 and June 30, 2017 (in thousands): Change in Unrealized Gain (Loss) on Derivatives Foreign Currency Translation Adjustments Gain (Loss) ( 1) Total As of December 31, 2017 $ (919 ) $ 46,232 $ 45,313 Other comprehensive income (loss) before reclassifications, before tax 189 (38,590 ) (38,401 ) Tax expense (45 ) — (45 ) Other comprehensive income (loss) before reclassifications, net of tax 144 (38,590 ) (38,446 ) Reclassification of gain from accumulated other comprehensive income, before tax (645 ) (9,011 ) (2) (9,656 ) Reclassification of tax expense 156 — 156 Reclassification of gain from accumulated other comprehensive income, after tax (489 ) (9,011 ) (9,500 ) Net current-period other comprehensive (loss) income, net of tax (345 ) (47,601 ) (47,946 ) As of June 30, 2018 $ (1,264 ) $ (1,369 ) $ (2,633 ) As of December 31, 2016 $ 3,619 $ (72,106 ) $ (68,487 ) Other comprehensive (loss) income before reclassifications, before tax (7,587 ) 72,017 64,430 Tax benefit 1,821 — 1,821 Other comprehensive (loss) income before reclassifications, net of tax (5,766 ) 72,017 66,251 Reclassification of loss from accumulated other comprehensive income, before tax 3,644 — 3,644 Reclassification of tax benefit (538 ) — (538 ) Reclassification of loss from accumulated other comprehensive income, after tax 3,106 — 3,106 Net current-period other comprehensive (loss) income, net of tax (2,660 ) 72,017 69,357 As of June 30, 2017 $ 959 $ (89 ) $ 870 (1) Taxes are not provided for foreign currency translation adjustments as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned. (2) Cumulative foreign currency translation adjustments eliminated upon the sale of CRM.

Stock-Based Incentive Plans

Stock-Based Incentive Plans	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Incentive Plans	Note 13. Stock-Based Incentive Plans Stock-based incentive plans compensation expense (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Service-based stock appreciation rights ("SARs") $ 2,675 $ 1,731 $ 4,023 $ 3,331 Service-based restricted stock units ("RSUs") 2,634 2,114 4,790 4,318 Market performance-based restricted stock units 959 170 1,305 174 Operating performance-based restricted stock units 1,185 371 2,032 407 Total stock-based compensation expense $ 7,453 $ 4,386 $ 12,150 $ 8,230 During the six months ended June 30, 2018 , we issued stock-based compensatory awards with contract terms agreed upon by us and the respective individuals, as approved by the Compensation Committee of our Board of Directors. The awards with service conditions generally vest ratably over four years, subject to forfeiture unless service conditions are met. Market performance-based awards cliff vest after three years subject to the rank of our total shareholder’s return for the three -year period ending December 31, 2020 relative to the total shareholder returns for a peer group of companies. Operating performance-based awards cliff vest after three years subject to the achievement of certain thresholds of cumulative adjusted free cash flow for the three year period ending 2020. Compensation expense related to awards granted during 2018 for the three and six months ended June 30, 2018 was $3.4 million and $3.9 million , respectively. Stock-based compensation agreements issued during the six months ended June 30, 2018 , representing potential shares and their weighted average grant date fair values by type follows (shares in thousands, fair value in dollars): Six Months Ended June 30, 2018 Shares Weighted Average Grant Date Fair Value Service-based SARs 634 $ 27.87 Service-based RSUs 227 $ 91.91 Market performance-based RSUs 41 $ 99.97 Operating performance-based RSUs 41 $ 88.38

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 14. Income Taxes Our effective income tax rate from continuing operations for the three months ended June 30, 2018 was (5.5)% compared with 5.2% for the three months ended June 30, 2017 . For the six months ended June 30, 2018 , the effective income tax rate from continuing operations was 7.0% compared with 10.6% for the six months ended June 30, 2017 . Our effective income tax rate fluctuates based on, among other factors, changes in pretax income in countries with varying statutory tax rates, changes in valuation allowances, changes in tax credits and incentives, and changes in unrecognized tax benefits associated with uncertain tax positions. Compared with the three and six months ended June 30, 2017, the lower effective tax rates for the three and six months ended June 30, 2018 were primarily attributable to the impact of the reduction to the U.S. federal statutory tax rate as a result of the U.S. “Tax Cuts and Jobs Act” (the “Tax Act”), the benefit of foreign derived intangible income partially offset by the repeal of the U.S. domestic production activity deduction, certain tax law changes in the UK that occurred during the three months ended December 31, 2017 and the impact of discrete tax items. During the three months ended June 30, 2018, we entered into an audit settlement impacting one of our uncertain tax positions. This audit settlement resulted in the recognition of an additional of $1.7 million in income tax expense.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Income (Loss) Per Share	Note 15. Net Income (Loss) Per Share Reconciliation of the shares used in the basic and diluted earnings per share computations for the three and six months ended June 30, 2018 and June 30, 2017 are as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Basic weighted average shares outstanding 48,487 48,140 48,406 48,104 Add effects of share-based compensation instruments (1) 851 163 857 137 Diluted weighted average shares outstanding 49,338 48,303 49,263 48,241 (1) Excluded from the computation of diluted earnings per share were stock options, SARs and restricted share units totaling 0.7 million and 1.8 million shares as of June 30, 2018 and June 30, 2017 , respectively , because to include them would be anti-dilutive.

Geographic and Segment Informat

Geographic and Segment Information	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Geographic and Segment Information	Note 16. Geographic and Segment Information We identify operating segments based on the way we manage, evaluate and internally report our business activities for purposes of allocating resources and assessing performance. We have two reportable segments: Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment generates its revenue from the development, production and sale of cardiopulmonary products, heart valves and advanced circulatory support. Cardiopulmonary products include oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae and other related accessories. Heart valves include mechanical heart valves, tissue heart valves and related repair products. Advanced circulatory support, which represents our recently acquired TandemLife business, includes temporary life support product kits that can include a combination of pumps, oxygenators, and cannulae. The Neuromodulation segment generates its revenue from the design, development and marketing of neuromodulation therapy systems for the treatment of drug-resistant epilepsy and treatment-resistant depression. Neuromodulation products include the VNS Therapy System, which consists of an implantable pulse generator, a lead that connects the generator to the vagus nerve, and other accessories. On January 16, 2018, we acquired the remaining 86% outstanding interest in ImThera which is also included in our Neuromodulation segment. ImThera manufactures an implantable device for the treatment of obstructive sleep apnea that stimulates multiple tongue muscles via the hypoglossal nerve, which opens the airway while a patient is sleeping. “Other” includes corporate shared service expenses for finance, legal, human resources and information technology and corporate business development (“New Ventures”). New Ventures is focused on new growth platforms and identification of other opportunities for expansion. Effective January 1, 2018, we began to include the results of heart failure within the Neuromodulation segment for internal reporting purposes in order to manage and evaluate business activities for purposes of allocating resources and assessing performance. Previously, the results of heart failure were reported within “Other”. Segment results for the three and six months ended June 30, 2017 have been recast to conform to the current period presentation. Net sales of our reportable segments include revenues from the sale of products they each develop and manufacture or distribute. We define segment income as operating income before merger and integration, restructuring and amortization of intangibles. We operate under three geographic regions: United States, Europe, and Rest of world. The table below presents net sales by operating segment and geographic region (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Cardiopulmonary United States $ 42,139 $ 39,719 $ 80,584 $ 71,895 Europe 35,916 33,959 72,786 64,568 Rest of world 58,584 50,467 108,399 94,980 136,639 124,145 261,769 231,443 Heart Valves United States 6,147 6,205 12,683 12,274 Europe 11,863 10,684 23,979 21,031 Rest of world 15,792 17,552 28,182 33,042 33,802 34,441 64,844 66,347 Advanced Circulatory Support United States 5,468 — 5,468 — Europe 353 — 353 — Rest of world 194 — 194 — 6,015 — 6,015 — Cardiac Surgery United States 53,754 45,924 98,735 84,169 Europe 48,132 44,643 97,118 85,599 Rest of world 74,570 68,019 136,775 128,022 176,456 158,586 332,628 297,790 Neuromodulation United States 89,395 81,405 167,387 155,064 Europe 11,943 9,514 22,234 17,443 Rest of world 9,315 6,096 14,876 11,667 110,653 97,015 204,497 184,174 Other 389 242 771 704 Totals United States 143,149 127,329 266,122 239,233 Europe (1) (2) 60,075 54,157 119,352 103,042 Rest of world 84,274 74,357 152,422 140,393 Total (3) $ 287,498 $ 255,843 $ 537,896 $ 482,668 (1) Net sales include $8.4 million and $9.2 million in the United Kingdom, our country of domicile, for the three months ended June 30, 2018 and June 30, 2017 , respectively. Net sales in the United Kingdom were $16.6 million and $17.3 million for the six months ended June 30, 2018 and June 30, 2017 , respectively. (2) Europe sales include those countries in which we have a direct sales presence, whereas European countries in which we sell through distributors are included in Rest of world. (3) No single customer represented over 10% of our consolidated net sales and no country’s net sales exceeded 10% of our consolidated sales except for the U.S. Operating income by segment is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, Operating Income from Continuing Operations 2018 2017 2018 2017 Cardiac Surgery $ 16,337 $ 23,773 $ 26,595 $ 39,806 Neuromodulation 61,389 51,264 100,123 92,020 Other (41,417 ) (33,037 ) (64,237 ) (49,903 ) Total reportable segment income from continuing operations 36,309 42,000 62,481 81,923 Merger and integration expenses 4,409 3,512 7,369 5,698 Restructuring expenses 476 2,597 2,357 12,627 Amortization of intangibles 9,817 8,116 18,618 16,076 Operating income from continuing operations $ 21,607 $ 27,775 $ 34,137 $ 47,522 Assets by reportable segment (in thousands): Assets June 30, 2018 December 31, 2017 Cardiac Surgery $ 1,535,096 $ 1,386,032 Neuromodulation 764,348 532,894 Other (1) 297,692 334,276 Discontinued operations — 250,689 Total assets $ 2,597,136 $ 2,503,891 (1) Other includes the impact of ASU 2016-16. Refer to “ Note 18. New Accounting Pronouncements .” Capital expenditures by segment (in thousands): Three Months Ended June 30, Six Months Ended June 30, Capital expenditures 2018 2017 2018 2017 Cardiac Surgery $ 4,594 $ 3,957 $ 7,725 $ 7,751 Neuromodulation 500 517 847 1,978 Other 1,256 1,148 2,699 2,806 Discontinued operations — 1,185 925 2,388 Total $ 6,350 $ 6,807 $ 12,196 $ 14,923 The changes in the carrying amount of goodwill by reportable segment for the six months ended June 30, 2018 were as follows (in thousands): Neuromodulation Cardiac Surgery Other Total December 31, 2017 $ 315,943 $ 425,882 $ 42,417 $ 784,242 Goodwill as a result of acquisitions (1) 82,596 118,917 — 201,513 Foreign currency adjustments — (20,058 ) — (20,058 ) June 30, 2018 $ 398,539 $ 524,741 $ 42,417 $ 965,697 (1) Goodwill recognized as a result of the ImThera and TandemLife acquisitions. Refer to “ Note 3. Business Combinations .” Property, plant and equipment, net by geography are as follows (in thousands): PP&E June 30, 2018 December 31, 2017 United States $ 64,298 $ 62,154 Europe 111,045 119,133 Rest of world 10,813 11,072 Total $ 186,156 $ 192,359

Supplemental Financial Informat

Supplemental Financial Information	6 Months Ended
	Jun. 30, 2018
Balance Sheet Related Disclosures [Abstract]
Supplemental Financial Information	Note 17. Supplemental Financial Information Inventories consisted of the following (in thousands): June 30, 2018 December 31, 2017 Raw materials $ 35,509 $ 39,810 Work-in-process 22,573 18,206 Finished goods 99,749 86,454 $ 157,831 $ 144,470 Inventories are reported net of the provision for obsolescence. The provision, which reflects normal obsolescence and includes components that are phased out or expired, totaled $9.3 million and $10.5 million at June 30, 2018 and December 31, 2017 , respectively. Accrued liabilities and other consisted of the following (in thousands): June 30, 2018 December 31, 2017 CRM purchase price adjustment payable to MicroPort Scientific Corporation $ 14,891 $ — Other amounts payable to MicroPort Scientific Corporation 6,419 — Product remediation (1) 9,296 16,811 Legal and administrative costs 12,619 6,082 Provisions for agents, returns and other 6,236 8,134 Royalty costs 3,162 3,615 Contract liabilities 3,330 2,900 Restructuring related liabilities 3,113 3,560 Derivative contract liabilities (2) 2,719 1,294 Contingent consideration (3) 2,684 — Research and development costs 1,172 797 Product warranty obligations 940 1,476 Deferred consideration — 14,300 Uncertain tax positions — 2,536 Escrow indemnity liabilities - Caisson — 2,000 Government grants — 1,174 Other accrued expenses 19,572 14,263 $ 86,153 $ 78,942 (1) Refer to “ Note 6. Product Remediation Liability ” (2) Refer to “ Note 10. Derivatives and Risk Management ” (3) Refer to “ Note 8. Fair Value Measurements ”

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Jun. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	Note 18. New Accounting Pronouncements In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities . Update 2016-01 requires equity investments that do not result in consolidation and are not accounted for under the equity method to be measured at fair value with changes recognized in net income. However, an entity may elect to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We made this election beginning January 1, 2018, resulting in no material impact to our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This guidance requires lessees to recognize most leases in their balance sheets as lease liabilities with corresponding right-of-use assets and to provide enhanced disclosures. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements , which provides certain practical expedients including an option to apply transition provisions of the new standard, including its disclosure requirements, at its adoption date instead of at the beginning of the earliest comparative period presented. We are in the process of assessing available practical expedients, including the transition provision that we have elected to apply, implementing lease accounting software and evaluating the effect this standard will have on our consolidated financial statements and related disclosures. The standard will be effective for us on January 1, 2019. In June 2016, the FASB issued ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in this update are effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The modified-retrospective approach is generally applicable through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. We are currently evaluating the effect this standard will have on our consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. Update 2016-15 provides guidance on the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. We adopted this update on January 1, 2018 resulting in no material impact to our consolidated statements of cash flows. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory . This update simplifies the accounting for the income tax consequences of transfers of assets from one unit of a corporation to another unit or subsidiary by eliminating an accounting exception that prevents the recognition of current and deferred income tax consequences for such “intra-entity transfers” until the assets have been sold to an outside party. We adopted this update on January 1, 2018 and recognized the following balance sheet adjustments (in thousands): Balance at December 31, 2017 Adjustment due to ASU No. 2016-16 Balance at January 1, 2018 Assets Prepaid expenses and other current assets $ 39,037 $ (12,604 ) $ 26,433 Deferred tax assets, net 11,559 58,301 69,860 Other assets 75,984 (68,127 ) 7,857 Equity Accumulated deficit $ (39,664 ) $ (22,430 ) $ (62,094 ) In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . This update removes step 2 of the goodwill impairment test that compares the implied fair value of goodwill with its carrying amount. Instead, an impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge will be recorded by the amount a reporting unit’s carrying amount exceeds its fair value. The update is effective for annual periods after December 15, 2019, including interim periods within those annual reporting periods with early adoption permitted. In March 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business . This update clarifies when a set of assets and activities is a business. We adopted this update on January 1, 2018. The ImThera and TandemLife acquisitions were considered acquisitions of a business. Refer to “ Note 3. Business Combinations ” for a discussion of our acquisitions of ImThera and TandemLife. In March 2017, the FASB issued ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post Retirement Benefit Cost . This update requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. We adopted this update on January 1, 2018, resulting in an immaterial impact to our consolidated financial statements. The condensed consolidated statements of income for the three and six months ended June 30, 2017 have been recast for the adoption of this update. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This update simplifies the accounting for nonemployee share-based payment transactions. The amendment specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The update is effective for annual periods after December 15, 2018, including interim periods within those annual reporting periods with early adoption permitted. We do not expect the adoption of this update to have a material effect on our consolidated financial statements.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Event	Note 19. Subsequent Event In July 2018, we borrowed $60.0 million under our June 2017 finance contract with the European Investment Bank to support financing of certain of our R&D projects. Repayment installments, with interest, are due semi-annually, beginning June 30, 2022 and ending June 30, 2026. The interest rate is LIBOR plus 0.966% .

Unaudited Condensed Consolida26

Unaudited Condensed Consolidated Financial Statements (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements of LivaNova as of, and for the three and six months ended June 30, 2018 and June 30, 2017 , have been prepared in accordance with U.S. GAAP for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying condensed consolidated balance sheet of LivaNova at December 31, 2017 has been derived from audited financial statements contained in our 2017 Form 10-K, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair statement of the operating results of LivaNova and its subsidiaries, for the three and six months ended June 30, 2018 and are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 . The financial information presented herein should be read in conjunction with the audited consolidated financial statements and notes thereto accompanying our 2017 Form 10-K.
Revenue Recognition	We generate our revenue through contracts with customers that primarily consist of hospitals, healthcare institutions, distributors and other organizations. Revenue is measured based on consideration specified in a contract with a customer, and excludes amounts collected on behalf of third parties. We measure the consideration based upon the estimated amount to be received. The amount of consideration we ultimately receive varies depending upon the return terms, sales rebates, discounts, and other incentives that we may offer, which are accounted for as variable consideration when estimating the amount of revenue to recognize. The estimate of variable consideration requires significant judgment. We have historically experienced a low rate of product returns and the total dollar value of product returns has not been significant to our financial statements. We recognize revenue when a performance obligation is satisfied by transferring the control of a product or providing service to a customer. Some of our contracts include the purchase of multiple products and/or services. In such cases, we allocate the transaction price based upon the relative estimated stand-alone price of each product and/or service sold. We record state and local sales taxes net; that is, we exclude sales tax from revenue. Typically, our contracts do not have a significant financing component. We incur incremental commission fees paid to the sales force associated with the sale of products. We apply the practical expedient within ASC 606-10-50-22 and have elected to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset the entity would otherwise recognize is one year or less. As a result, no commissions are capitalized as contract costs at June 30, 2018 . The following is a description of the principal activities (separated by reportable segments) from which we generate our revenue. Cardiac Surgery Products and Services The Cardiac Surgery (“CS”) segment has three primary product lines: cardiopulmonary products, heart valves and advanced circulatory support. Cardiopulmonary products include oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae and other related accessories. Heart valves include mechanical heart valves, tissue heart valves and related repair products. Technical services include installation, repair and maintenance of cardiopulmonary equipment under service contracts or upon customer request. Cardiopulmonary products may include performance obligations associated with assembly and installation of equipment. Accordingly, we allocate a portion of the sales prices to installation obligations and recognize that revenue when the service is provided. We recognize revenue for equipment and accessory product sales when control of the equipment or product passes to the customer. Heart valve revenue is recognized when control passes to the customer, usually at the point of surgery. Advanced circulatory support revenue, which represents our recently acquired TandemLife business, is principally derived from the sale of temporary life support product kits that can include a combination of pumps, oxygenators, and cannulae. Revenue is recognized when control passes to the customer, usually at the point of shipment. Technical service agreements generally provide for upfront payments in advance of rendering services or periodic billing over the contract term. Amounts billed in advance are deferred and recognized as revenue when the performance obligation is satisfied. Technical services are not a significant component of CS revenue and have been presented with the related equipment and accessories revenue. Neuromodulation Products Our Neuromodulation (“NM”) segment generates its revenue from the sale of neuromodulation therapy systems for the treatment of drug-resistant epilepsy, treatment-resistant depression and obstructive sleep apnea. The NM product line includes the VNS Therapy System, which consists of an implantable pulse generator, a lead that connects the generator to the vagus nerve, and other accessories. The NM product line also includes an implantable device for the treatment of obstructive sleep apnea that stimulates multiple tongue muscles via the hypoglossal nerve, which opens the airway while a patient is sleeping. We recognize revenue for product sales when control passes to the customer. Discontinued Operations: Cardiac Rhythm Management Products CRM generated revenue from the sale of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. CRM devices include high-voltage defibrillators and low-voltage pacemakers. We recognize revenue for product sales when control passes to the customer. Contract Balances Due to the nature of our products and services, revenue producing activities may result in contract assets and contract liabilities which are insignificant to our financial position and results of operations. These activities relate primarily to CS technical services contracts for short-term and multi-year service agreements. Contract assets are primarily comprised of unbilled revenues, which occur when a performance obligation has been completed, but not billed to the customer. Contract liabilities are made up of deferred revenue, which occurs when a customer pays for a service, before a performance obligation has been completed.
Derivatives	Due to the global nature of our operations, we are exposed to foreign currency exchange rate fluctuations. In addition, due to certain loans with floating interest rates, we are also subject to the impact of changes in interest rates on our interest payments. We enter into foreign currency exchange rate (“FX”) derivative contracts and interest rate swap contracts to reduce the impact of foreign currency rate and interest rate fluctuations on earnings and cash flow. We measure all outstanding derivatives each period end at fair value and report the fair value as either financial assets or liabilities in the condensed consolidated balance sheets. We do not enter into derivative contracts for speculative purposes. At inception of the contract, the derivative is designated as either a freestanding derivative or a hedge. Derivatives that are not designated as hedging instruments are referred to as freestanding derivatives with changes in fair value included in earnings. If the derivative qualifies for hedge accounting, depending on the nature of the hedge and hedge effectiveness, changes in the fair value of the derivative will either be recognized immediately in earnings or recorded in accumulated other comprehensive income (“AOCI”) until the hedged item is recognized in earnings upon settlement/termination. FX derivative gains and losses in AOCI are reclassified to the condensed consolidated statements of income as shown in the tables below and interest rate swap gains and losses in AOCI are reclassified to interest expense in the condensed consolidated statements of income. We evaluate hedge effectiveness at inception and on an ongoing basis. If a derivative is no longer expected to be highly effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is recorded in earnings. Cash flows from derivative contracts are reported as operating activities in the condensed consolidated statements of cash flows.
New Accounting Pronouncements	In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities . Update 2016-01 requires equity investments that do not result in consolidation and are not accounted for under the equity method to be measured at fair value with changes recognized in net income. However, an entity may elect to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. We made this election beginning January 1, 2018, resulting in no material impact to our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This guidance requires lessees to recognize most leases in their balance sheets as lease liabilities with corresponding right-of-use assets and to provide enhanced disclosures. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements , which provides certain practical expedients including an option to apply transition provisions of the new standard, including its disclosure requirements, at its adoption date instead of at the beginning of the earliest comparative period presented. We are in the process of assessing available practical expedients, including the transition provision that we have elected to apply, implementing lease accounting software and evaluating the effect this standard will have on our consolidated financial statements and related disclosures. The standard will be effective for us on January 1, 2019. In June 2016, the FASB issued ASU Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): The amendments in this update require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in this update are effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The modified-retrospective approach is generally applicable through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. We are currently evaluating the effect this standard will have on our consolidated financial statements and related disclosures. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. Update 2016-15 provides guidance on the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. We adopted this update on January 1, 2018 resulting in no material impact to our consolidated statements of cash flows. In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory . This update simplifies the accounting for the income tax consequences of transfers of assets from one unit of a corporation to another unit or subsidiary by eliminating an accounting exception that prevents the recognition of current and deferred income tax consequences for such “intra-entity transfers” until the assets have been sold to an outside party. We adopted this update on January 1, 2018 and recognized the following balance sheet adjustments (in thousands): Balance at December 31, 2017 Adjustment due to ASU No. 2016-16 Balance at January 1, 2018 Assets Prepaid expenses and other current assets $ 39,037 $ (12,604 ) $ 26,433 Deferred tax assets, net 11,559 58,301 69,860 Other assets 75,984 (68,127 ) 7,857 Equity Accumulated deficit $ (39,664 ) $ (22,430 ) $ (62,094 ) In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . This update removes step 2 of the goodwill impairment test that compares the implied fair value of goodwill with its carrying amount. Instead, an impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge will be recorded by the amount a reporting unit’s carrying amount exceeds its fair value. The update is effective for annual periods after December 15, 2019, including interim periods within those annual reporting periods with early adoption permitted. In March 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business . This update clarifies when a set of assets and activities is a business. We adopted this update on January 1, 2018. The ImThera and TandemLife acquisitions were considered acquisitions of a business. Refer to “ Note 3. Business Combinations ” for a discussion of our acquisitions of ImThera and TandemLife. In March 2017, the FASB issued ASU No. 2017-07, Compensation—Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post Retirement Benefit Cost . This update requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. We adopted this update on January 1, 2018, resulting in an immaterial impact to our consolidated financial statements. The condensed consolidated statements of income for the three and six months ended June 30, 2017 have been recast for the adoption of this update. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This update simplifies the accounting for nonemployee share-based payment transactions. The amendment specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The update is effective for annual periods after December 15, 2018, including interim periods within those annual reporting periods with early adoption permitted. We do not expect the adoption of this update to have a material effect on our consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2018
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The following table presents the acquisition date fair value of the consideration transferred and the fair value of our interest in ImThera prior to the acquisition (in thousands): Cash $ 78,332 Contingent consideration 112,744 Fair value of our interest in ImThera prior to the acquisition (1) 25,580 Fair value of consideration transferred $ 216,656 (1) The fair value of our previously-held interest in ImThera was determined based on the fair value of total consideration transferred and application of a discount for lack of control. As a result, we recognized a gain of $11.5 million for the fair value in excess of our carrying value of $14.1 million . The gain is reflected as “Gain on acquisitions” on our condensed consolidated statement of income for the six months ended June 30, 2018 . The following table presents the acquisition date fair value of the consideration transferred (in thousands): Cash $ 203,671 Contingent consideration 40,190 Fair value of consideration transferred $ 243,861
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the preliminary purchase price allocation at fair value for the TandemLife acquisition (in thousands): In-process research and development (1) (2) (3) $ 110,977 Trade names (1) 11,539 Developed technology (1) 6,387 Goodwill 118,917 Inventory 10,296 Other assets and liabilities, net 3,632 Deferred income tax liabilities, net (3) (17,887 ) Net assets acquired $ 243,861 (1) The amounts above are included in “Intangible assets, net” in the condensed consolidated balance sheet at June 30, 2018 . Trade names and developed technology are amortized over remaining useful lives of 15 and 2 years, respectively. (2) The fair value of in-process research and development ("IPR&D") was determined using the income approach, which is a valuation technique that provides a fair value estimate based on the market participant expectations of cash flows the asset would generate. The cash flows were discounted commensurate with the level of risk associated with the asset. The discount rates were developed after assigning a probability of success to achieving the projected cash flows based on the current stage of development, inherent uncertainty in reaching certain regulatory milestones and risks associated with commercialization of the product. (3) The amounts include provisional estimates based on the information available as of the acquisition date. The Company is gathering additional information necessary to finalize the estimated fair values for deferred tax assets acquired and IPR&D. The following table presents the preliminary purchase price allocation at fair value for the ImThera acquisition including certain measurement period adjustments (in thousands): Initial Purchase Price Allocation Measurement Period Adjustments (1) Adjusted Purchase Price Allocation In-process research and development (2) $ 151,605 $ 10,677 $ 162,282 Developed technology 5,661 (5,661 ) — Goodwill 87,063 (4,467 ) 82,596 Deferred income tax liabilities, net (3) (27,980 ) (1,278 ) (29,258 ) Other assets and liabilities, net 836 200 1,036 Net assets acquired $ 217,185 $ (529 ) $ 216,656 (1) During the second quarter of 2018, measurement period adjustments were recorded based upon new information obtained about facts and circumstances that existed as of the acquisition date. (2) The fair value of in-process research and development ("IPR&D") was determined using the income approach, which is a valuation technique that provides a fair value estimate based on the market participant expectations of cash flows the asset would generate. The cash flows were discounted commensurate with the level of risk associated with the asset. The discount rates were developed after assigning a probability of success to achieving the projected cash flows based on the current stage of development, inherent uncertainty in reaching certain regulatory milestones and risks associated with commercialization of the product. The IPR&D amount is included in “Intangible assets, net” in the condensed consolidated balance sheet at June 30, 2018 . (3) The amount includes a provisional estimate for deferred tax assets acquired.
Schedule of Business Acquisitions by Acquisition, Contingent Consideration	The TandemLife business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs (in thousands): TandemLife Acquisition Fair value at April 4, 2018 Valuation Technique Unobservable Input Ranges Regulatory milestone-based payments $ 40,190 Discounted cash flow Discount rate 4.2% - 4.8% Probability of payments 75% - 95% Projected payment years 2019 - 2020 The ImThera business combination involved contingent consideration arrangements composed of potential cash payments upon the achievement of a certain regulatory milestone and a sales-based earnout associated with sales of products covered by the purchase agreement. The sales-based earnout was valued using projected sales from our internal strategic plan. Both arrangements are Level 3 fair value measurements and include the following significant unobservable inputs (in thousands): ImThera Acquisition Fair value at January 16, 2018 Valuation Technique Unobservable Input Ranges Regulatory milestone-based payment $ 50,429 Discounted cash flow Discount rate 4.3% - 4.7% Probability of payment 85% - 95% Projected payment years 2020 - 2021 Sales-based earnout 62,315 Monte Carlo simulation Risk-adjusted discount rate 11.5% Credit risk discount rate 4.7% - 5.8% Revenue volatility 29.3% Probability of payment 85% - 95% Projected years of earnout 2020 - 2025 $ 112,744

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Components of discontinued operations	The following table represents assets and liabilities of CRM presented as assets and liabilities of discontinued operations in the condensed consolidated balance sheet: December 31, 2017 Accounts receivable, net $ 64,684 Inventories 54,097 Prepaid taxes 14,725 Prepaid and other assets 3,498 Property, plant and equipment, net 12,104 Deferred tax assets, net 2,517 Investments 6,098 Intangible assets, net 92,966 Assets of discontinued operations $ 250,689 Accounts payable 26,501 Accrued liabilities and other 7,669 Taxes payable 5,084 Accrued employee compensation and benefits 30,753 Deferred income taxes liability 8,068 Liabilities of discontinued operations $ 78,075 The following table represents the financial results of CRM presented as net (loss) income from discontinued operations in the condensed consolidated statements of income: Three Months Ended June 30, Six Months Ended June 30, 2018 (1) 2017 2018 (1) 2017 Revenues $ 27,206 $ 65,544 $ 87,313 $ 123,824 Cost of sales 10,391 24,800 32,529 46,285 Gross profit 16,815 40,744 54,784 77,539 Selling, general and administrative expenses 15,073 25,960 46,899 50,997 Research and development 5,929 9,118 17,210 18,377 Merger and integration expenses — 10 — 32 Restructuring expenses — (1,479 ) 651 (1,359 ) Amortization of intangibles — 3,565 — 7,019 Revaluation gain on assets and liabilities held for sale — — (1,213 ) — Loss on sale of CRM 214 — 214 — Total operating expenses 21,216 37,174 63,761 75,066 Operating (loss) income from discontinued operations (4,401 ) 3,570 (8,977 ) 2,473 Foreign exchange and other (losses) gains (67 ) (402 ) 12 (172 ) (Loss) income from discontinued operations, before tax (4,468 ) 3,168 (8,965 ) 2,301 Income tax (benefit) expense (6 ) 54 (1,165 ) 54 Losses from equity method investments — (1,295 ) (1,211 ) (2,384 ) Net (loss) income from discontinued operations (1) $ (4,462 ) $ 1,819 $ (9,011 ) $ (137 ) (1) CRM financial results for the three and six month periods ended June 30, 2018 include activity through the close of the sale on April 30, 2018.

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The following table presents the Plans’ accruals, inventory obsolescence and other reserves, recorded in connection with the Reorganization Plans including the balances and activity related to the discontinued operations, (in thousands): Employee Severance and Other Termination Costs Other Total Balance at December 31, 2017 $ 3,889 $ 2,625 $ 6,514 Charges 2,544 464 3,008 Cash payments and adjustments (5,431 ) (470 ) (5,901 ) Balance at June 30, 2018 $ 1,002 $ 2,619 $ 3,621
Schedule of Restructuring Expense by Reportable Segment	The following table presents restructuring expense by reportable segment, with discontinued operations included (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Cardiac Surgery (1) $ 398 $ 501 $ 1,739 $ 6,503 Neuromodulation 11 (233 ) 17 439 Other 67 2,329 601 5,685 Restructuring expense from continuing operations 476 2,597 2,357 12,627 Discontinued operations — (1,479 ) 651 (1,359 ) Total $ 476 $ 1,118 $ 3,008 $ 11,268 (1) Cardiac Surgery restructuring expense for the six months ended June 30, 2017 included building and equipment impairment and additional costs of $5.1 million related to the Suzhou, China facility exit plan.

Product Remediation Liability (

Product Remediation Liability (Tables)	6 Months Ended
	Jun. 30, 2018
Environmental Remediation Obligations [Abstract]
Product Liability Contingencies	Changes in the carrying amount of the product remediation liability are as follows (in thousands): Balance at December 31, 2017 $ 27,546 Remediation activity (7,272 ) Effect of changes in foreign currency exchange rates (557 ) Balance at June 30, 2018 (1) $ 19,717 (1) At June 30, 2018 , the product remediation liability balance is held within ‘Accrued liabilities and other’ and ‘Other long-term liabilities’ in the condensed consolidated balance sheet.

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2018
Investments [Abstract]
Schedule of Cost Method Investments	Our cost-method investments are included in “Investments” in the condensed consolidated balance sheets and consist of our equity positions in the following privately-held companies (in thousands): June 30, 2018 December 31, 2017 Respicardia Inc. (1) $ 17,705 $ 17,422 ImThera Medical, Inc. (2) — 12,900 Rainbow Medical Ltd. (3) 1,140 1,172 MD Start II (4) 1,164 1,199 Highlife S.A.S. (5) 1,104 — Other 17 17 $ 21,130 $ 32,710 (1) Respicardia Inc. (“Respicardia”) is a privately funded U.S. company developing an implantable device designed to restore a more natural breathing pattern during sleep in patients with central sleep apnea ("CSA") by transvenously stimulating the phrenic nerve. We have a loan outstanding to Respicardia with a carrying amount of $0.5 million , as of June 30, 2018 , which is included in “Prepaid expenses and other current assets” in the condensed consolidated balance sheet. (2) On January 16, 2018, we acquired the remaining outstanding interests in ImThera. Refer to “ Note 3. Business Combinations ”. (3) Rainbow Medical Ltd. is a private Israeli venture capital company that seeds and grows companies developing medical devices in a diverse range of medical fields. (4) MD Start II is a private venture capital collaboration for the development of medical device technology in Europe. (5) Due to an additional investment by a third party during the three months ended June 30, 2018 , our equity interest in Highlife S.A.S. (“Highlife”) decreased to 17.5% from 24.6% . We determined that we no longer had significant influence over Highlife and it is now considered a cost method investment. The carrying amount of our equity-method investment in Highlife was $1.8 million at December 31, 2017 .

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements on a Recurring Basis	The following table provides information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands): Fair Value as of June 30, 2018 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Liabilities: Derivative liabilities - designated as cash flow hedges (foreign currency exchange rate "FX") $ 1,209 $ — $ 1,209 $ — Derivative liabilities - designated as cash flow hedges (interest rate swaps) 1,221 — 1,221 — Derivative liabilities - freestanding instruments (FX) 827 — 827 — Contingent consideration (1) 181,133 — — 181,133 $ 184,390 $ — $ 3,257 $ 181,133 Fair Value as of December 31, 2017 Fair Value Measurements Using Inputs Considered as: Level 1 Level 2 Level 3 Assets: Derivative assets - freestanding instruments (FX) $ 519 $ — $ 519 $ — $ 519 $ — $ 519 $ — Liabilities: Derivative liabilities - designated as cash flow hedges (FX) $ 460 $ — $ 460 $ — Derivative liabilities - designated as cash flow hedges (interest rate swaps) 1,585 — 1,585 — Contingent consideration (1) 33,973 — — 33,973 $ 36,018 $ — $ 2,045 $ 33,973 (1) The contingent consideration liability represents contingent payments related to five completed acquisitions: Cellplex PTY Ltd., Inversiones Drilltex SAS, Caisson, ImThera and TandemLife.
Reconciliation of Beginning and Ending Balances of Contingent Consideration	The following table provides a reconciliation of the beginning and ending balance of the contingent consideration liability (in thousands): Total contingent consideration liability at December 31, 2017 $ 33,973 Purchase price - ImThera contingent consideration 112,744 Purchase price - TandemLife contingent consideration 40,190 Payments (196 ) Changes in fair value (1) (5,546 ) Effect of changes in foreign currency exchange rates (32 ) Total contingent consideration liability at June 30, 2018 181,133 Less current portion of contingent consideration liability at June 30, 2018 2,684 Long-term portion of contingent consideration liability at June 30, 2018 $ 178,449 (1) Includes a decrease of $6.1 million due to the delay in the timing of anticipated regulatory approval for ImThera. See “ Note 3. Business Combinations ” for additional discussion.

Financing Arrangements (Tables)

Financing Arrangements (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The outstanding principal amount of long-term debt (in thousands, except interest rates): June 30, 2018 December 31, 2017 Maturity Interest Rate European Investment Bank (1) $ 58,213 $ 69,893 June 2021 0.95 % Mediocredito Italiano (2) 8,406 9,118 December 2023 0.50% - 3.10% Banca del Mezzogiorno (3) 4,137 5,499 December 2019 0.50% - 3.15% Region Wallonne 756 845 December 2023 and June 2033 0.00% - 2.45% Mediocredito Italiano - mortgages and other 536 997 September 2021 and September 2026 0.80% - 1.30% Bpifrance (ex-Oséo) — 1,450 — 2.58 % Total long-term facilities 72,048 87,802 Less current portion of long-term debt 21,635 25,844 Total long-term debt $ 50,413 $ 61,958 (1) The European Investment Bank (“EIB”) loan was obtained in July 2014 to support product development projects. The interest rate for the EIB loan is reset by the lender each quarter based on the Euribor. Interest payments are paid quarterly and principal payments are paid semi-annually. (2) We obtained the Mediocredito Italiano Bank loan in July 2016 as part of the Fondo Innovazione Teconologica program implemented by the Italian Ministry of Education. (3) The Banca del Mezzogiorno loan was obtained in January 2015 to support R&D projects as a part of the Large Strategic Project program of the Italian Ministry of Education.

Derivatives and Risk Manageme34

Derivatives and Risk Management (Tables)	6 Months Ended
	Jun. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Derivative Contracts Designated Cash Flow Hedges	Notional amounts of open derivative contracts designated as cash flow hedges (in thousands): Description of Derivative Contract June 30, 2018 December 31, 2017 FX derivative contracts to be exchanged for British Pounds $ 11,655 $ 16,847 FX derivative contracts to be exchanged for Japanese Yen 22,122 32,302 FX derivative contracts to be exchanged for Canadian Dollars 15,779 16,494 FX derivative contracts to be exchanged for Euros 38,581 — Interest rate swap contracts 46,570 55,965 $ 134,707 $ 121,608
Unrealized Gain (Loss) in AOCI	After-tax net loss associated with derivatives designated as cash flow hedges recorded in the ending balance of AOCI and the amount expected to be reclassified to earnings in the next twelve months (in thousands): Description of Derivative Contract June 30, 2018 Amount Expected to be Reclassified to Earnings in Next 12 Months FX derivative contracts $ (1,011 ) $ (1,011 ) Interest rate swap contracts (253 ) (64 ) $ (1,264 ) $ (1,075 )
Schedule of Cash Flow Hedges Included in AOCI	Pre-tax gains (losses) for derivative contracts designated as cash flow hedges recognized in Other Comprehensive Income (Loss) (“OCI”) and the amount reclassified to earnings from AOCI (in thousands): Three Months Ended June 30, 2018 2017 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other gains (losses) $ (25 ) $ (1,358 ) $ (755 ) $ (532 ) FX derivative contracts SG&A — 549 — 544 Interest rate swap contracts Interest expense — (17 ) — 543 $ (25 ) $ (826 ) $ (755 ) $ 555 Six Months Ended June 30, 2018 2017 Description of Derivative Contract Location in Earnings of Reclassified Gain or Loss Gains Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings Losses Recognized in OCI (Losses) Gains Reclassified from AOCI to Earnings FX derivative contracts Foreign exchange and other gains (losses) $ 189 $ (512 ) $ (7,587 ) $ (5,210 ) FX derivative contracts SG&A — 1,174 — 1,354 Interest rate swap contracts Interest expense — (17 ) — 212 $ 189 $ 645 $ (7,587 ) $ (3,644 )
Schedule of Fair Value of Derivative Instruments in Statement of Financial Position	The following tables present the fair value on a gross basis, and the location of, derivative contracts reported in the condensed consolidated balance sheets (in thousands): June 30, 2018 Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Interest rate swap contracts Accrued liabilities $ 683 Interest rate swap contracts Other long-term liabilities 538 FX derivative contracts Accrued liabilities 1,209 Total derivatives designated as hedging instruments 2,430 Derivatives Not Designated as Hedging Instruments FX derivative contracts Accrued liabilities 827 Total derivatives not designated as hedging instruments 827 Total derivatives $ 3,257 December 31, 2017 Asset Derivatives Liability Derivatives Derivatives Designated as Hedging Instruments Balance Sheet Location Fair Value (1) Balance Sheet Location Fair Value (1) Interest rate swap contracts Prepaid expenses and other current assets $ — Accrued liabilities $ 834 Interest rate swap contracts Other assets — Other long-term liabilities 751 FX derivative contracts Prepaid expenses and other current assets — Accrued liabilities 460 Total derivatives designated as hedging instruments — 2,045 Derivatives Not Designated as Hedging Instruments FX derivative contracts Prepaid expenses and other current assets 519 Accrued liabilities — Total derivatives not designated as hedging instruments 519 — Total derivatives $ 519 $ 2,045 (1) For the classification of inputs used to evaluate the fair value of our derivatives, refer to “ Note 8. Fair Value Measurements .”

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The table below presents the change in each component of AOCI, net of tax, and the reclassifications out of AOCI into net income for the six months ended June 30, 2018 and June 30, 2017 (in thousands): Change in Unrealized Gain (Loss) on Derivatives Foreign Currency Translation Adjustments Gain (Loss) ( 1) Total As of December 31, 2017 $ (919 ) $ 46,232 $ 45,313 Other comprehensive income (loss) before reclassifications, before tax 189 (38,590 ) (38,401 ) Tax expense (45 ) — (45 ) Other comprehensive income (loss) before reclassifications, net of tax 144 (38,590 ) (38,446 ) Reclassification of gain from accumulated other comprehensive income, before tax (645 ) (9,011 ) (2) (9,656 ) Reclassification of tax expense 156 — 156 Reclassification of gain from accumulated other comprehensive income, after tax (489 ) (9,011 ) (9,500 ) Net current-period other comprehensive (loss) income, net of tax (345 ) (47,601 ) (47,946 ) As of June 30, 2018 $ (1,264 ) $ (1,369 ) $ (2,633 ) As of December 31, 2016 $ 3,619 $ (72,106 ) $ (68,487 ) Other comprehensive (loss) income before reclassifications, before tax (7,587 ) 72,017 64,430 Tax benefit 1,821 — 1,821 Other comprehensive (loss) income before reclassifications, net of tax (5,766 ) 72,017 66,251 Reclassification of loss from accumulated other comprehensive income, before tax 3,644 — 3,644 Reclassification of tax benefit (538 ) — (538 ) Reclassification of loss from accumulated other comprehensive income, after tax 3,106 — 3,106 Net current-period other comprehensive (loss) income, net of tax (2,660 ) 72,017 69,357 As of June 30, 2017 $ 959 $ (89 ) $ 870 (1) Taxes are not provided for foreign currency translation adjustments as translation adjustments are related to earnings that are intended to be reinvested in the countries where earned. (2) Cumulative foreign currency translation adjustments eliminated upon the sale of CRM.

Stock-Based Incentive Plan (Tab

Stock-Based Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Stock Options, Activity	Stock-based incentive plans compensation expense (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Service-based stock appreciation rights ("SARs") $ 2,675 $ 1,731 $ 4,023 $ 3,331 Service-based restricted stock units ("RSUs") 2,634 2,114 4,790 4,318 Market performance-based restricted stock units 959 170 1,305 174 Operating performance-based restricted stock units 1,185 371 2,032 407 Total stock-based compensation expense $ 7,453 $ 4,386 $ 12,150 $ 8,230 Stock-based compensation agreements issued during the six months ended June 30, 2018 , representing potential shares and their weighted average grant date fair values by type follows (shares in thousands, fair value in dollars): Six Months Ended June 30, 2018 Shares Weighted Average Grant Date Fair Value Service-based SARs 634 $ 27.87 Service-based RSUs 227 $ 91.91 Market performance-based RSUs 41 $ 99.97 Operating performance-based RSUs 41 $ 88.38

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income Per Share	Reconciliation of the shares used in the basic and diluted earnings per share computations for the three and six months ended June 30, 2018 and June 30, 2017 are as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Basic weighted average shares outstanding 48,487 48,140 48,406 48,104 Add effects of share-based compensation instruments (1) 851 163 857 137 Diluted weighted average shares outstanding 49,338 48,303 49,263 48,241 (1) Excluded from the computation of diluted earnings per share were stock options, SARs and restricted share units totaling 0.7 million and 1.8 million shares as of June 30, 2018 and June 30, 2017 , respectively , because to include them would be anti-dilutive.

Geographic and Segment Inform38

Geographic and Segment Information (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Revenue from External Customers by Geographic Areas	The table below presents net sales by operating segment and geographic region (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Cardiopulmonary United States $ 42,139 $ 39,719 $ 80,584 $ 71,895 Europe 35,916 33,959 72,786 64,568 Rest of world 58,584 50,467 108,399 94,980 136,639 124,145 261,769 231,443 Heart Valves United States 6,147 6,205 12,683 12,274 Europe 11,863 10,684 23,979 21,031 Rest of world 15,792 17,552 28,182 33,042 33,802 34,441 64,844 66,347 Advanced Circulatory Support United States 5,468 — 5,468 — Europe 353 — 353 — Rest of world 194 — 194 — 6,015 — 6,015 — Cardiac Surgery United States 53,754 45,924 98,735 84,169 Europe 48,132 44,643 97,118 85,599 Rest of world 74,570 68,019 136,775 128,022 176,456 158,586 332,628 297,790 Neuromodulation United States 89,395 81,405 167,387 155,064 Europe 11,943 9,514 22,234 17,443 Rest of world 9,315 6,096 14,876 11,667 110,653 97,015 204,497 184,174 Other 389 242 771 704 Totals United States 143,149 127,329 266,122 239,233 Europe (1) (2) 60,075 54,157 119,352 103,042 Rest of world 84,274 74,357 152,422 140,393 Total (3) $ 287,498 $ 255,843 $ 537,896 $ 482,668 (1) Net sales include $8.4 million and $9.2 million in the United Kingdom, our country of domicile, for the three months ended June 30, 2018 and June 30, 2017 , respectively. Net sales in the United Kingdom were $16.6 million and $17.3 million for the six months ended June 30, 2018 and June 30, 2017 , respectively. (2) Europe sales include those countries in which we have a direct sales presence, whereas European countries in which we sell through distributors are included in Rest of world. (3) No single customer represented over 10% of our consolidated net sales and no country’s net sales exceeded 10% of our consolidated sales except for the U.S.
Schedule of Segment Reporting Information, by Segment	Operating income by segment is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, Operating Income from Continuing Operations 2018 2017 2018 2017 Cardiac Surgery $ 16,337 $ 23,773 $ 26,595 $ 39,806 Neuromodulation 61,389 51,264 100,123 92,020 Other (41,417 ) (33,037 ) (64,237 ) (49,903 ) Total reportable segment income from continuing operations 36,309 42,000 62,481 81,923 Merger and integration expenses 4,409 3,512 7,369 5,698 Restructuring expenses 476 2,597 2,357 12,627 Amortization of intangibles 9,817 8,116 18,618 16,076 Operating income from continuing operations $ 21,607 $ 27,775 $ 34,137 $ 47,522 Assets by reportable segment (in thousands): Assets June 30, 2018 December 31, 2017 Cardiac Surgery $ 1,535,096 $ 1,386,032 Neuromodulation 764,348 532,894 Other (1) 297,692 334,276 Discontinued operations — 250,689 Total assets $ 2,597,136 $ 2,503,891 (1) Other includes the impact of ASU 2016-16. Refer to “ Note 18. New Accounting Pronouncements .” Capital expenditures by segment (in thousands): Three Months Ended June 30, Six Months Ended June 30, Capital expenditures 2018 2017 2018 2017 Cardiac Surgery $ 4,594 $ 3,957 $ 7,725 $ 7,751 Neuromodulation 500 517 847 1,978 Other 1,256 1,148 2,699 2,806 Discontinued operations — 1,185 925 2,388 Total $ 6,350 $ 6,807 $ 12,196 $ 14,923
Schedule of Goodwill	The changes in the carrying amount of goodwill by reportable segment for the six months ended June 30, 2018 were as follows (in thousands): Neuromodulation Cardiac Surgery Other Total December 31, 2017 $ 315,943 $ 425,882 $ 42,417 $ 784,242 Goodwill as a result of acquisitions (1) 82,596 118,917 — 201,513 Foreign currency adjustments — (20,058 ) — (20,058 ) June 30, 2018 $ 398,539 $ 524,741 $ 42,417 $ 965,697 (1) Goodwill recognized as a result of the ImThera and TandemLife acquisitions. Refer to “ Note 3. Business Combinations .”
Long-lived Assets by Geographic Areas	Property, plant and equipment, net by geography are as follows (in thousands): PP&E June 30, 2018 December 31, 2017 United States $ 64,298 $ 62,154 Europe 111,045 119,133 Rest of world 10,813 11,072 Total $ 186,156 $ 192,359

Supplemental Financial Inform39

Supplemental Financial Information (Tables)	6 Months Ended
	Jun. 30, 2018
Balance Sheet Related Disclosures [Abstract]
Inventories	Inventories consisted of the following (in thousands): June 30, 2018 December 31, 2017 Raw materials $ 35,509 $ 39,810 Work-in-process 22,573 18,206 Finished goods 99,749 86,454 $ 157,831 $ 144,470
Accrued Liabilities	Accrued liabilities and other consisted of the following (in thousands): June 30, 2018 December 31, 2017 CRM purchase price adjustment payable to MicroPort Scientific Corporation $ 14,891 $ — Other amounts payable to MicroPort Scientific Corporation 6,419 — Product remediation (1) 9,296 16,811 Legal and administrative costs 12,619 6,082 Provisions for agents, returns and other 6,236 8,134 Royalty costs 3,162 3,615 Contract liabilities 3,330 2,900 Restructuring related liabilities 3,113 3,560 Derivative contract liabilities (2) 2,719 1,294 Contingent consideration (3) 2,684 — Research and development costs 1,172 797 Product warranty obligations 940 1,476 Deferred consideration — 14,300 Uncertain tax positions — 2,536 Escrow indemnity liabilities - Caisson — 2,000 Government grants — 1,174 Other accrued expenses 19,572 14,263 $ 86,153 $ 78,942 (1) Refer to “ Note 6. Product Remediation Liability ” (2) Refer to “ Note 10. Derivatives and Risk Management ” (3) Refer to “ Note 8. Fair Value Measurements ”

New Accounting Pronouncements (

New Accounting Pronouncements (Tables)	6 Months Ended
	Jun. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	We adopted this update on January 1, 2018 and recognized the following balance sheet adjustments (in thousands): Balance at December 31, 2017 Adjustment due to ASU No. 2016-16 Balance at January 1, 2018 Assets Prepaid expenses and other current assets $ 39,037 $ (12,604 ) $ 26,433 Deferred tax assets, net 11,559 58,301 69,860 Other assets 75,984 (68,127 ) 7,857 Equity Accumulated deficit $ (39,664 ) $ (22,430 ) $ (62,094 )

Unaudited Condensed Consolida41

Unaudited Condensed Consolidated Financial Statements (Narrative) (Details) - USD ($) $ in Thousands	Apr. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Disposal Groups, Including Discontinued Operations [Line Items]
Loans to equity method investees		$ 0	$ (6,834)
Contingent consideration		$ 178,449		$ 33,973
CRM Business Franchise
Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred	$ 195,900
Consideration transferred, cash	$ 9,200

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Accrued liabilities and other
Disaggregation of Revenue [Line Items]
Contract liability	$ 5.1	$ 3.8

Business Combinations - Narrati

Business Combinations - Narrative (Details) - USD ($) $ in Thousands	May 02, 2018	Apr. 04, 2018	Jan. 16, 2018	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Contingent consideration				$ 178,449	$ 178,449	$ 33,973
Caisson Interventional LLC
Business Acquisition [Line Items]
Percentage of voting interests acquired	51.00%
Debt forgiveness	$ 6,300
Cash	18,000			14,400
Contingent consideration				39,600	39,600
ImThera Medical, Inc.
Business Acquisition [Line Items]
Percentage of voting interests acquired			86.00%
Fair value of consideration transferred			$ 216,656
Cash			78,332
Contingent consideration			112,744
Revenue				100	200
Operating loss				(2,600)	(3,600)
TandemLife
Business Acquisition [Line Items]
Fair value of consideration transferred		$ 243,861
Cash		203,671
Contingent consideration		50,000
Revenue				6,000	6,000
Operating loss				(6,100)	6,100
Upfront costs		204,000
SG&A | ImThera Medical, Inc.
Business Acquisition [Line Items]
Acquisition-related expense				200	300
SG&A | TandemLife
Business Acquisition [Line Items]
Acquisition-related expense				$ 1,600	$ 1,900
Maximum | Caisson Interventional LLC
Business Acquisition [Line Items]
Fair value of consideration transferred	$ 72,000
Maximum | ImThera Medical, Inc.
Business Acquisition [Line Items]
Fair value of consideration transferred			$ 225,000
Maximum | TandemLife
Business Acquisition [Line Items]
Fair value of consideration transferred		$ 250,000

Business Combinations - Purchas

Business Combinations - Purchase Price Composition (Details) - USD ($) $ in Thousands	Apr. 04, 2018	Jan. 16, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Business Acquisition [Line Items]
Gain from acquisition			$ 0	$ 39,428	$ 11,484	$ 39,428
ImThera Medical, Inc.
Business Acquisition [Line Items]
Cash		$ 78,332
Contingent consideration		112,744
Fair value of our interest prior to the acquisition		25,580
Fair value of consideration transferred		$ 216,656
Gain from acquisition					11,500
Fair value in excess of carrying value adjustment					$ 14,100
TandemLife
Business Acquisition [Line Items]
Cash	$ 203,671
Contingent consideration	40,190
Fair value of consideration transferred	$ 243,861

Business Combinations - Prelimi

Business Combinations - Preliminary Purchase Price Allocation (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Apr. 04, 2018	Jan. 16, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	$ 965,697			$ 784,242
ImThera Medical, Inc.
Business Acquisition [Line Items]
Goodwill	82,596		$ 87,063
Goodwill, adjustment	(4,467)
Deferred income tax liabilities, net	(29,258)		(27,980)
Deferred income taxes, net, adjustment	(1,278)
Other assets and liabilities, net	1,036		836
Other assets and liabilities, net, adjustment	200
Net assets acquired	216,656		217,185
Net assets acquired, adjustment	$ (529)
TandemLife
Business Acquisition [Line Items]
Goodwill		$ 118,917
Inventory		10,296
Deferred income tax liabilities, net		(17,887)
Other assets and liabilities, net		3,632
Net assets acquired		243,861
Useful life	2 years
In Process Research and Development | ImThera Medical, Inc.
Business Acquisition [Line Items]
Intangible asset	$ 162,282		151,605
Intangible asset, adjustment	$ 10,677
In Process Research and Development | TandemLife
Business Acquisition [Line Items]
Intangible asset		110,977
Trade Names | TandemLife
Business Acquisition [Line Items]
Intangible asset		11,539
Useful life	15 years
Developed Technology | ImThera Medical, Inc.
Business Acquisition [Line Items]
Intangible asset	$ 0		$ 5,661
Intangible asset, adjustment	$ (5,661)
Developed Technology | TandemLife
Business Acquisition [Line Items]
Intangible asset		$ 6,387

Business Combinations - Conting

Business Combinations - Contingent Consideration (Details) - USD ($) $ in Thousands	Apr. 04, 2018	Jan. 16, 2018	Jun. 30, 2018	Dec. 31, 2017
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration			$ 178,449	$ 33,973
ImThera Medical, Inc.
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration		$ 112,744
ImThera Medical, Inc. | Discounted Cash Flow
Business Acquisition, Contingent Consideration [Line Items]
Regulatory milestone-based payment		$ 50,429
ImThera Medical, Inc. | Discounted Cash Flow | Minimum
Business Acquisition, Contingent Consideration [Line Items]
Discount rate		4.30%
Probability of payment		85.00%
ImThera Medical, Inc. | Discounted Cash Flow | Maximum
Business Acquisition, Contingent Consideration [Line Items]
Discount rate		4.70%
Probability of payment		95.00%
ImThera Medical, Inc. | Monte Carlo Simulation
Business Acquisition, Contingent Consideration [Line Items]
Sales-based earnout		$ 62,315
Risk adjusted discount rate		11.50%
Revenue volatility		29.30%
ImThera Medical, Inc. | Monte Carlo Simulation | Minimum
Business Acquisition, Contingent Consideration [Line Items]
Probability of payment		85.00%
Credit risk rate		5.00%
ImThera Medical, Inc. | Monte Carlo Simulation | Maximum
Business Acquisition, Contingent Consideration [Line Items]
Probability of payment		95.00%
Credit risk rate		6.00%
TandemLife
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration	$ 50,000
TandemLife | Discounted Cash Flow
Business Acquisition, Contingent Consideration [Line Items]
Regulatory milestone-based payment	$ 40,190
TandemLife | Discounted Cash Flow | Minimum
Business Acquisition, Contingent Consideration [Line Items]
Discount rate	4.20%
Probability of payment	75.00%
TandemLife | Discounted Cash Flow | Maximum
Business Acquisition, Contingent Consideration [Line Items]
Discount rate	4.80%
Probability of payment	95.00%

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Millions	Apr. 30, 2018	Jun. 30, 2018	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock-based compensation		$ 2.1	$ 0.3
CRM Business Franchise
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred	$ 195.9
Consideration transferred, cash	$ 9.2
Transition services		0.9
Capital expenditure		$ 0.9	2.4
Depreciation and amortization			$ 9.9

Discontinued Operations (Assets

Discontinued Operations (Assets And Liabilities Classified As Held For Sale) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets of discontinued operations	$ 0	$ 250,689
Liabilities of discontinued operations	$ 0	78,075
CRM Business Franchise | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net		64,684
Inventories		54,097
Prepaid taxes		14,725
Prepaid and other assets		3,498
Property, plant and equipment, net		12,104
Deferred tax assets, net		2,517
Investments		6,098
Intangible assets, net		92,966
Assets of discontinued operations		250,689
Accounts payable		26,501
Accrued liabilities and other		7,669
Taxes payable		5,084
Accrued employee compensation and benefits		30,753
Deferred income taxes liability		8,068
Liabilities of discontinued operations		$ 78,075

Discontinued Operations (Operat

Discontinued Operations (Operating Gains And Losses) (Details) - CRM Business Franchise - Discontinued Operations, Held-for-sale - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues	$ 27,206	$ 65,544	$ 87,313	$ 123,824
Cost of sales	10,391	24,800	32,529	46,285
Gross profit	16,815	40,744	54,784	77,539
Selling, general and administrative expenses	15,073	25,960	46,899	50,997
Research and development	5,929	9,118	17,210	18,377
Merger and integration expenses	0	10	0	32
Restructuring expenses	0	(1,479)	651	(1,359)
Amortization of intangibles	0	3,565	0	7,019
Revaluation gain on assets and liabilities held for sale	0	0	(1,213)	0
Loss on sale of CRM	214	0	214	0
Total operating expenses	21,216	37,174	63,761	75,066
Operating (loss) income from discontinued operations	(4,401)	3,570	(8,977)	2,473
Foreign exchange and other (losses) gains	(67)	(402)	12	(172)
(Loss) income from discontinued operations, before tax	(4,468)	3,168	(8,965)	2,301
Income tax (benefit) expense	(6)	54	(1,165)	54
Losses from equity method investments	0	(1,295)	(1,211)	(2,384)
Net income (loss) from discontinued operations	$ (4,462)	$ 1,819	$ (9,011)	$ (137)

Restructuring (Narrative) (Deta

Restructuring (Narrative) (Details) - Suzhou Industrial Park Facility - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Apr. 30, 2018	Jun. 30, 2017
Restructuring Cost and Reserve [Line Items]
Employee severance		$ (0.5)
Proceeds from sale of facility	$ 13.3
Building and Equipment
Restructuring Cost and Reserve [Line Items]
Asset Impairment Charges		$ (4.6)

Restructuring (Accrual Detail)

Restructuring (Accrual Detail) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Restructuring Reserve [Roll Forward]
Charges	$ 476	$ 2,597	$ 2,357	$ 12,627
2015 and 2016 Reorganization Plans
Restructuring Reserve [Roll Forward]
Beginning liability balance			6,514
Charges			3,008
Cash payments and adjustments			(5,901)
Ending liability balance	3,621		3,621
2015 and 2016 Reorganization Plans | Employee Severance and Other Termination Costs
Restructuring Reserve [Roll Forward]
Beginning liability balance			3,889
Charges			2,544
Cash payments and adjustments			(5,431)
Ending liability balance	1,002		1,002
2015 and 2016 Reorganization Plans | Other
Restructuring Reserve [Roll Forward]
Beginning liability balance			2,625
Charges			464
Cash payments and adjustments			(470)
Ending liability balance	$ 2,619		$ 2,619

Restructuring (Restructuring Ex

Restructuring (Restructuring Expense by Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Restructuring Cost and Reserve [Line Items]
Charges	$ 476	$ 2,597	$ 2,357	$ 12,627
Discontinued operations	0	(1,479)	651	(1,359)
Restructuring charges, net	476	1,118	3,008	11,268
Operating Segments | Cardiac Surgery
Restructuring Cost and Reserve [Line Items]
Charges	398	501	1,739	6,503
Operating Segments | Neuromodulation
Restructuring Cost and Reserve [Line Items]
Charges	11	(233)	17	439
Other
Restructuring Cost and Reserve [Line Items]
Charges	$ 67	$ 2,329	$ 601	5,685
Building and Equipment | Suzhou Industrial Park Facility
Restructuring Cost and Reserve [Line Items]
Restructuring charges, net				$ 5,100

Product Remediation Liability53

Product Remediation Liability (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Accrual for Environmental Loss Contingencies [Roll Forward]
Product remediation accrual, beginning balance	$ 27,546
Remediation activity	(7,272)
Effect of changes in foreign currency exchange rates	(557)
Product remediation accrual, ending balance	$ 19,717

Investments (Cost-Method Invest

Investments (Cost-Method Investments) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 29, 2018	Dec. 31, 2017
Schedule of Cost-method Investments [Line Items] (Deprecated 2018-01-31)
Cost method investments	$ 21,130		$ 32,710
Ownership percentage (percent)	24.60%
Cost Method Investee | Respicardia | Prepaid expenses and other current assets
Schedule of Cost-method Investments [Line Items] (Deprecated 2018-01-31)
Outstanding loans	$ 500
Respicardia
Schedule of Cost-method Investments [Line Items] (Deprecated 2018-01-31)
Cost method investments	17,705		17,422
ImThera Medical, Inc.
Schedule of Cost-method Investments [Line Items] (Deprecated 2018-01-31)
Cost method investments	0		12,900
Rainbow Medical Ltd.
Schedule of Cost-method Investments [Line Items] (Deprecated 2018-01-31)
Cost method investments	1,140		1,172
MD Start II
Schedule of Cost-method Investments [Line Items] (Deprecated 2018-01-31)
Cost method investments	1,164		1,199
Highlife S.A.S.
Schedule of Cost-method Investments [Line Items] (Deprecated 2018-01-31)
Cost method investments	1,104		0
Equity method investments			1,800
Ownership percentage (percent)		17.50%
Other
Schedule of Cost-method Investments [Line Items] (Deprecated 2018-01-31)
Cost method investments	$ 17		$ 17

Fair Value Measurements (Assets

Fair Value Measurements (Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Liabilities:
Number of businesses acquired	5
Level 3
Liabilities:
Contingent consideration		$ 33,973
Fair Value, Measurements, Recurring
Assets:
Total assets		519
Liabilities:
Contingent consideration	$ 181,133	33,973
Total liabilities	184,390	36,018
Fair Value, Measurements, Recurring | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Liabilities:
Derivative liabilities	1,209	460
Fair Value, Measurements, Recurring | Derivatives Designated as Hedging Instruments | Interest Rate Contract
Liabilities:
Derivative liabilities	1,221	1,585
Fair Value, Measurements, Recurring | Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative Asset		519
Liabilities:
Derivative liabilities	827
Fair Value, Measurements, Recurring | Level 1
Assets:
Total assets		0
Liabilities:
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring | Level 1 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Liabilities:
Derivative liabilities	0	0
Fair Value, Measurements, Recurring | Level 1 | Derivatives Designated as Hedging Instruments | Interest Rate Contract
Liabilities:
Derivative liabilities	0	0
Fair Value, Measurements, Recurring | Level 1 | Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative Asset		0
Liabilities:
Derivative liabilities	0
Fair Value, Measurements, Recurring | Level 2
Assets:
Total assets		519
Liabilities:
Contingent consideration	0	0
Total liabilities	3,257	2,045
Fair Value, Measurements, Recurring | Level 2 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Liabilities:
Derivative liabilities	1,209	460
Fair Value, Measurements, Recurring | Level 2 | Derivatives Designated as Hedging Instruments | Interest Rate Contract
Liabilities:
Derivative liabilities	1,221	1,585
Fair Value, Measurements, Recurring | Level 2 | Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative Asset		519
Liabilities:
Derivative liabilities	827
Fair Value, Measurements, Recurring | Level 3
Assets:
Total assets		0
Liabilities:
Contingent consideration	181,133	33,973
Total liabilities	181,133	33,973
Fair Value, Measurements, Recurring | Level 3 | Derivatives Designated as Hedging Instruments | Foreign Exchange Contract
Liabilities:
Derivative liabilities	0	0
Fair Value, Measurements, Recurring | Level 3 | Derivatives Designated as Hedging Instruments | Interest Rate Contract
Liabilities:
Derivative liabilities	0	0
Fair Value, Measurements, Recurring | Level 3 | Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contract
Assets:
Derivative Asset		$ 0
Liabilities:
Derivative liabilities	$ 0

Fair Value Measurements - Conti

Fair Value Measurements - Contingent Consideration Reconciliation (Details) - Level 3 $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration, start	$ 33,973
Payments	196
Effect of changes in foreign currency exchange rates	(32)
Fair value, current liability	2,684
Fair value, non-current liability	178,449
ImThera Medical, Inc.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Purchase price - contingent consideration	112,744
Changes in fair value	(5,546)
TandemLife
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Purchase price - contingent consideration	40,190
Fair value, timing delay of anticipated regulatory approval\	$ 6,100

Financing Arrangements (Long-Te

Financing Arrangements (Long-Term Debt Outstanding, Revolving Credit and European Investment Bank Financing Agreement) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total long-term facilities	$ 72,048	$ 87,802
Less current portion of long-term debt	21,635	25,844
Total long-term debt	50,413	61,958
Loans Payable | European Investment Bank
Debt Instrument [Line Items]
Total long-term facilities	$ 58,213	69,893
Interest rate (percent)	0.95%
Loans Payable | Mediocredito Italiano
Debt Instrument [Line Items]
Total long-term facilities	$ 8,406	9,118
Loans Payable | Mediocredito Italiano | Minimum
Debt Instrument [Line Items]
Interest rate (percent)	0.50%
Loans Payable | Mediocredito Italiano | Maximum
Debt Instrument [Line Items]
Interest rate (percent)	3.10%
Loans Payable | Banca del Mezzogiorno
Debt Instrument [Line Items]
Total long-term facilities	$ 4,137	5,499
Loans Payable | Banca del Mezzogiorno | Minimum
Debt Instrument [Line Items]
Interest rate (percent)	0.50%
Loans Payable | Banca del Mezzogiorno | Maximum
Debt Instrument [Line Items]
Interest rate (percent)	3.15%
Loans Payable | Novalia SA
Debt Instrument [Line Items]
Total long-term facilities	$ 756	845
Loans Payable | Novalia SA | Minimum
Debt Instrument [Line Items]
Interest rate (percent)	0.00%
Loans Payable | Novalia SA | Maximum
Debt Instrument [Line Items]
Interest rate (percent)	2.45%
Loans Payable | Bpifrance
Debt Instrument [Line Items]
Total long-term facilities	$ 0	1,450
Interest rate (percent)	2.58%
Mortgages | Mediocredito Italiano
Debt Instrument [Line Items]
Total long-term facilities	$ 536	$ 997
Mortgages | Mediocredito Italiano | Minimum
Debt Instrument [Line Items]
Interest rate (percent)	0.80%
Mortgages | Mediocredito Italiano | Maximum
Debt Instrument [Line Items]
Interest rate (percent)	1.30%

Financing Arrangements (Details

Financing Arrangements (Details) € in Millions	Apr. 10, 2018USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Apr. 30, 2018USD ($)	Apr. 30, 2018EUR (€)	Apr. 29, 2018USD ($)	Apr. 29, 2018EUR (€)	Apr. 09, 2018USD ($)	Apr. 03, 2018USD ($)	Mar. 23, 2018USD ($)
Revolving Credit Facility
Debt Instrument [Line Items]
Short-term debt		$ 89,000,000	$ 58,200,000
Minimum | Revolving Credit Facility
Debt Instrument [Line Items]
Interest rate (percent)		0.10%	0.10%
Debt instrument, term		1 day	1 day
Maximum | Revolving Credit Facility
Debt Instrument [Line Items]
Interest rate (percent)		9.30%	9.30%
Debt instrument, term		180 days	180 days
Bridge Loan
Debt Instrument [Line Items]
Finance contract, borrowing base									$ 190,000,000	$ 190,000,000
Barclays Bank | London Interbank Offered Rate (LIBOR) | Revolving Credit Facility
Debt Instrument [Line Items]
Finance contract, borrowing base	$ 70,000,000							$ 40,000,000
Debt instrument, basis spread on variable rate	0.85%
European Investment Bank
Debt Instrument [Line Items]
Finance contract, borrowing base				$ 104,800,000	€ 90	$ 116,400,000	€ 100

Derivatives and Risk Manageme59

Derivatives and Risk Management (Narrative) (Details) - Derivatives Not Designated as Hedging Instruments - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Foreign Exchange Forward
Derivative [Line Items]
Notional amount	$ 256		$ 256		$ 231.9
Foreign Exchange Contract | Foreign exchange and other gains (losses)
Derivative [Line Items]
Gain (loss) on derivative	$ (4.1)	$ (5.4)	$ (11.7)	$ (7.2)

Derivatives and Risk Manageme60

Derivatives and Risk Management (Derivative Notional Amounts) (Details) - Derivatives Designated as Hedging Instruments - Cash Flow Hedging - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Derivative [Line Items]
Notional amount	$ 134,707	$ 121,608
After-tax, net unrealized losses on derivatives arising during period	(1,264)
Net amount expected to be reclassified to earnings in the next 12 months	(1,075)
Foreign Exchange Contract
Derivative [Line Items]
After-tax, net unrealized losses on derivatives arising during period	(1,011)
Net amount expected to be reclassified to earnings in the next 12 months	(1,011)
Foreign Exchange Contract | United Kingdom, Pounds
Derivative [Line Items]
Notional amount	11,655	16,847
Foreign Exchange Contract | Japan, Yen
Derivative [Line Items]
Notional amount	22,122	32,302
Foreign Exchange Contract | Canada, Dollars
Derivative [Line Items]
Notional amount	15,779	16,494
Foreign Exchange Contract | Euro Member Countries, Euro
Derivative [Line Items]
Notional amount	38,581	0
Interest Rate Swap Contracts
Derivative [Line Items]
Notional amount	46,570	$ 55,965
After-tax, net unrealized losses on derivatives arising during period	(253)
Net amount expected to be reclassified to earnings in the next 12 months	$ (64)

Derivatives and Risk Manageme61

Derivatives and Risk Management (Amount of Gain (Loss) Recognized in OCI and Income Statement) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Losses/Gains Recognized in OCI	$ 0	$ 0	$ 0	$ 0
Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Losses/Gains Recognized in OCI	(25)	(755)	189	(7,587)
(Losses) Gains Reclassified from AOCI to Earnings	(826)	555	645	(3,644)
Cash Flow Hedging | Foreign exchange and other gains (losses)
Derivative Instruments, Gain (Loss) [Line Items]
(Losses) Gains Reclassified from AOCI to Earnings	(1,358)	(532)	(512)	(5,210)
Cash Flow Hedging | SG&A
Derivative Instruments, Gain (Loss) [Line Items]
(Losses) Gains Reclassified from AOCI to Earnings	549	544	1,174	1,354
Cash Flow Hedging | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
(Losses) Gains Reclassified from AOCI to Earnings	(17)	543	(17)	212
Cash Flow Hedging | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Losses/Gains Recognized in OCI	(25)	(755)	189	(7,587)
Cash Flow Hedging | Interest Rate Swap Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Losses/Gains Recognized in OCI	$ 0	$ 0	$ 0	$ 0

Derivatives and Risk Manageme62

Derivatives and Risk Management (Fair Value of Derivative Instruments) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Total asset derivatives		$ 519
Total liability derivatives	$ 3,257	2,045
Derivatives Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Total asset derivatives		0
Total liability derivatives	2,430	2,045
Derivatives Designated as Hedging Instruments | Prepaid expenses and other current assets | Interest Rate Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives		0
Derivatives Designated as Hedging Instruments | Prepaid expenses and other current assets | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives		0
Derivatives Designated as Hedging Instruments | Accrued liabilities | Interest Rate Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	683	834
Derivatives Designated as Hedging Instruments | Accrued liabilities | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	1,209	460
Derivatives Designated as Hedging Instruments | Other assets | Interest Rate Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives		0
Derivatives Designated as Hedging Instruments | Other long-term liabilities | Interest Rate Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	538	751
Derivatives Not Designated as Hedging Instruments
Derivatives, Fair Value [Line Items]
Total asset derivatives		519
Total liability derivatives	827	0
Derivatives Not Designated as Hedging Instruments | Prepaid expenses and other current assets | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total asset derivatives		519
Derivatives Not Designated as Hedging Instruments | Accrued liabilities | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Total liability derivatives	$ 827	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) $ in Thousands, € in Millions

May 15, 2018USD ($)

Oct. 06, 2016USD ($)

Apr. 01, 2016USD ($)

Jun. 30, 2018USD ($)installmentnotice

Jun. 30, 2018EUR (€)

Dec. 31, 2004USD ($)

Jul. 31, 2018claim

Jun. 30, 2018EUR (€)installmentnotice

Dec. 31, 2017USD ($)

Aug. 27, 2015non-conformity

Oct. 30, 2009USD ($)

Oct. 30, 2009EUR (€)

Other Commitments [Line Items]

Accrual for environmental loss contingencies

$ 19,717

$ 27,546

Estimate of possible loss

19,700

€ 17

Settled Litigation

Other Commitments [Line Items]

Litigation settlement

$ 480

$ 480

Legal fees

$ 58

Threatened Litigation | Regional Internal Revenue Office of Lombardy

Other Commitments [Line Items]

Losses under dispute

$ 72,900

€ 62.6

$ 119,500

€ 102.6

Number of equal installments | installment

5

5

Number of notice of assessments | notice

3

3

FDA Warning Letter

Other Commitments [Line Items]

Number of observed non-conformities | non-conformity

2

SNIA | Pending Litigation | SNIA s.p.a

Other Commitments [Line Items]

Compensation sought

$ 4,000,000

SNIA | Settled Litigation | Sorin S.p.A. | Positive Outcome of Litigation

Other Commitments [Line Items]

Litigation settlement

$ 340

Forecast

Other Commitments [Line Items]

Pending claims, number | claim

135

Stockholders' Equity (Comprehen

Stockholders' Equity (Comprehensive Income) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	$ 1,815,314
Ending Balance	1,783,034
Change in Unrealized Gain (Loss) on Derivatives
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(919)	$ 3,619
Other comprehensive (loss) income before reclassifications, before tax	189	(7,587)
Tax expense (benefit)	(45)	1,821
Other comprehensive (loss) income before reclassifications, net of tax	144	(5,766)
Reclassification of loss (gain) from accumulated other comprehensive income, before tax	(645)	3,644
Reclassification of tax expense (benefit)	156	(538)
Reclassification of loss (gain) from accumulated other comprehensive income, after tax	(489)	3,106
Net current-period other comprehensive (loss) income, net of tax	(345)	(2,660)
Ending Balance	(1,264)	959
Foreign Currency Translation Adjustments Gain (Loss)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	46,232	(72,106)
Other comprehensive (loss) income before reclassifications, before tax	(38,590)	72,017
Tax expense (benefit)	0	0
Other comprehensive (loss) income before reclassifications, net of tax	(38,590)	72,017
Reclassification of loss (gain) from accumulated other comprehensive income, before tax	(9,011)	0
Reclassification of tax expense (benefit)	0	0
Reclassification of loss (gain) from accumulated other comprehensive income, after tax	(9,011)	0
Net current-period other comprehensive (loss) income, net of tax	(47,601)	72,017
Ending Balance	(1,369)	(89)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	45,313	(68,487)
Other comprehensive (loss) income before reclassifications, before tax	(38,401)	64,430
Tax expense (benefit)	(45)	1,821
Other comprehensive (loss) income before reclassifications, net of tax	(38,446)	66,251
Reclassification of loss (gain) from accumulated other comprehensive income, before tax	(9,656)	3,644
Reclassification of tax expense (benefit)	156	(538)
Reclassification of loss (gain) from accumulated other comprehensive income, after tax	(9,500)	3,106
Net current-period other comprehensive (loss) income, net of tax	(47,946)	69,357
Ending Balance	$ (2,633)	$ 870

Stock-Based Incentive Plan (Com

Stock-Based Incentive Plan (Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 7,453	$ 4,386	$ 12,150	$ 8,230
Share-based compensation arrangement, compensation cost	3,400		3,900
Service-based stock appreciation rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,675	1,731	4,023	3,331
Service-based restricted stock units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2,634	2,114	4,790	4,318
Market performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	959	170	$ 1,305	174
Share-based compensation arrangement, vesting period			3 years
Operating performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,185	$ 371	$ 2,032	$ 407
Share-based compensation arrangement, vesting period			3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement, vesting period			4 years

Stock-Based Incentive Plan (Exe

Stock-Based Incentive Plan (Executed Agreements) (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Service-based stock appreciation rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	634
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 27.87
Service-based restricted stock units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	227
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 91.91
Market performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	41
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 99.97
Operating performance-based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares (in shares) | shares	41
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 88.38

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Effective tax rate (percent)	(5.50%)	5.20%	7.00%	10.60%
Audit settlement	$ 1.7

Net Income (Loss) Per Share (Sc

Net Income (Loss) Per Share (Schedule of Earnings Per Share, Basic and Diluted) (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Earnings Per Share [Abstract]
Basic weighted average shares outstanding (in Shares)	48,487	48,140	48,406	48,104
Add effects of share-based compensation instruments (in Shares)	851	163	857	137
Diluted weighted average shares outstanding (in Shares)	49,338	48,303	49,263	48,241

Net Income (Loss) Per Share (Na

Net Income (Loss) Per Share (Narrative of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares shares in Millions	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	0.7	1.8

Geographic and Segment Inform70

Geographic and Segment Information (Segment Info) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018USD ($)geographic_region	Jun. 30, 2017USD ($)	Jun. 30, 2018USD ($)segmentgeographic_region	Jun. 30, 2017USD ($)	Jan. 16, 2018	Dec. 31, 2017USD ($)
Segment Reporting [Abstract]
Reportable segments | segment			2
Number of geographic regions in which entity operates | geographic_region	3		3
Segment Reporting Information [Line Items]
Ownership percentage (percent)	24.60%		24.60%
Net sales	$ 287,498	$ 255,843	$ 537,896	$ 482,668
Total reportable segment income from continuing operations	36,309	42,000	62,481	81,923
Merger and integration expenses	4,409	3,512	7,369	5,698
Charges	476	2,597	2,357	12,627
Amortization of intangibles	9,817	8,116	18,618	16,076
Operating income from continuing operations	21,607	27,775	34,137	47,522
Assets	2,597,136		2,597,136			$ 2,503,891
Capital expenditures	6,350	6,807	12,196	14,923
Operating Segments | Cardiac Surgery
Segment Reporting Information [Line Items]
Total reportable segment income from continuing operations			26,595	39,806
Charges	398	501	1,739	6,503
Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Total reportable segment income from continuing operations			100,123	92,020
Charges	11	(233)	17	439
Other
Segment Reporting Information [Line Items]
Total reportable segment income from continuing operations	(41,417)	(33,037)	(64,237)	(49,903)
Charges	67	2,329	601	5,685
Assets	297,692		297,692			334,276
Capital expenditures	1,256	1,148	2,699	2,806
ImThera Medical, Inc.
Segment Reporting Information [Line Items]
Ownership percentage (percent)					86.00%
Continuing Operations | Operating Segments
Segment Reporting Information [Line Items]
Net sales	287,498	255,843	537,896	482,668
Continuing Operations | Operating Segments | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	176,456	158,586	332,628	297,790
Total reportable segment income from continuing operations	16,337	23,773
Assets	1,535,096		1,535,096			1,386,032
Capital expenditures	4,594	3,957	7,725	7,751
Continuing Operations | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales	110,653	97,015	204,497	184,174
Total reportable segment income from continuing operations	61,389	51,264
Assets	764,348		764,348			532,894
Capital expenditures	500	517	847	1,978
Discontinued Operations
Segment Reporting Information [Line Items]
Assets	0		0			$ 250,689
Capital expenditures	0	1,185	925	2,388
United States | Continuing Operations | Operating Segments
Segment Reporting Information [Line Items]
Net sales	143,149	127,329	266,122	239,233
United States | Continuing Operations | Operating Segments | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	53,754	45,924	98,735	84,169
United States | Continuing Operations | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales	89,395	81,405	167,387	155,064
Europe | Continuing Operations | Operating Segments
Segment Reporting Information [Line Items]
Net sales	60,075	54,157	119,352	103,042
Europe | Continuing Operations | Operating Segments | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	48,132	44,643	97,118	85,599
Europe | Continuing Operations | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales	11,943	9,514	22,234	17,443
Rest of world | Continuing Operations | Operating Segments
Segment Reporting Information [Line Items]
Net sales	84,274	74,357	152,422	140,393
Rest of world | Continuing Operations | Operating Segments | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	74,570	68,019	136,775	128,022
Rest of world | Continuing Operations | Operating Segments | Neuromodulation
Segment Reporting Information [Line Items]
Net sales	9,315	6,096	14,876	11,667
Rest of world | Continuing Operations | Other
Segment Reporting Information [Line Items]
Net sales	389	242	771	704
UNITED KINGDOM
Segment Reporting Information [Line Items]
Net sales	8,400	9,200	16,600	17,300
Cardiopulmonary | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	136,639	124,145	261,769	231,443
Cardiopulmonary | United States | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	42,139	39,719	80,584	71,895
Cardiopulmonary | Europe | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	35,916	33,959	72,786	64,568
Cardiopulmonary | Rest of world | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	58,584	50,467	108,399	94,980
Heart Valves | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	33,802	34,441	64,844	66,347
Heart Valves | United States | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	6,147	6,205	12,683	12,274
Heart Valves | Europe | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	11,863	10,684	23,979	21,031
Heart Valves | Rest of world | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	15,792	17,552	28,182	33,042
Advanced Circulatory Support | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	6,015	0	6,015	0
Advanced Circulatory Support | United States | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	5,468	0	5,468	0
Advanced Circulatory Support | Europe | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	353	0	353	0
Advanced Circulatory Support | Rest of world | Cardiac Surgery
Segment Reporting Information [Line Items]
Net sales	$ 194	$ 0	$ 194	$ 0

Geographic and Segment Inform71

Geographic and Segment Information (Changes in Carrying Amount of Goodwill) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Goodwill [Roll Forward]
Goodwill, beginning	$ 784,242
Goodwill as a result of acquisitions	201,513
Foreign currency adjustments	(20,058)
Goodwill, ending	965,697
Operating Segments | Neuromodulation
Goodwill [Roll Forward]
Goodwill, beginning	315,943
Goodwill as a result of acquisitions	82,596
Foreign currency adjustments	0
Goodwill, ending	398,539
Operating Segments | Cardiac Surgery
Goodwill [Roll Forward]
Goodwill, beginning	425,882
Goodwill as a result of acquisitions	118,917
Foreign currency adjustments	(20,058)
Goodwill, ending	524,741
Other
Goodwill [Roll Forward]
Goodwill, beginning	42,417
Goodwill as a result of acquisitions	0
Foreign currency adjustments	0
Goodwill, ending	$ 42,417

Geographic and Segment Inform72

Geographic and Segment Information (Geographic Areas) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 186,156	$ 192,359
United States
Segment Reporting Information [Line Items]
Property, plant and equipment, net	64,298	62,154
Europe
Segment Reporting Information [Line Items]
Property, plant and equipment, net	111,045	119,133
Rest of world
Segment Reporting Information [Line Items]
Property, plant and equipment, net	$ 10,813	$ 11,072

Supplemental Financial Inform73

Supplemental Financial Information (Summary of Inventory) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 35,509	$ 39,810
Work-in-process	22,573	18,206
Finished goods	99,749	86,454
Inventory, Net	157,831	144,470
Provision for obsolescence	$ 9,300	$ 10,500

Supplemental Financial Inform74

Supplemental Financial Information (Summary of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]
CRM purchase price adjustment payable to MicroPort Scientific Corporation	$ 14,891	$ 0
Other amounts payable to MicroPort Scientific Corporation	6,419	0
Product remediation	9,296	16,811
Legal and administrative costs	12,619	6,082
Provisions for agents, returns and other	6,236	8,134
Royalty costs	3,162	3,615
Contract liabilities	3,330	2,900
Restructuring related liabilities	3,113	3,560
Derivative contract liabilities	2,719	1,294
Contingent consideration	2,684	0
Research and development costs	1,172	797
Product warranty obligations	940	1,476
Deferred consideration	0	14,300
Uncertain tax positions	0	2,536
Escrow indemnity liabilities - Caisson	0	2,000
Government grants	0	1,174
Other accrued expenses	19,572	14,263
Accrued liabilities	$ 86,153	$ 78,942

New Accounting Pronouncements75

New Accounting Pronouncements (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expenses and other current assets	$ 35,621	$ 26,433	$ 39,037
Deferred tax assets, net	65,539	69,860	11,559
Other assets	5,489	7,857	75,984
Accumulated deficit	$ (33,755)	$ (62,094)	(39,664)
Calculated under Revenue Guidance in Effect before Topic 606
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expenses and other current assets			39,037
Deferred tax assets, net			11,559
Other assets			75,984
Accumulated deficit			(39,664)
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expenses and other current assets			(12,604)
Deferred tax assets, net			58,301
Other assets			(68,127)
Accumulated deficit			$ (22,430)

Subsequent Event (Details)

Subsequent Event (Details) - European Investment Bank - Subsequent Event $ in Millions	1 Months Ended
	Jul. 31, 2018USD ($)
Subsequent Event [Line Items]
Borrowed funds	$ 60
London Interbank Offered Rate (LIBOR)
Subsequent Event [Line Items]
Debt instrument, basis spread on variable rate	0.966%